 
 
 
A Randomized, Placebo 
Controlled Clinical Trial of 
SOM230 (Pasireotide LAR) In 
Severe Polycystic Liver Disease. 
 
NCT#  [STUDY_ID_REMOVED] 
 
October 14, 2014 
 Confidential  Page 1 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Medical Affairs  
SOM230C  
Clinical Trial Protocol CSOM230XUS30T  
 
 
A Randomized, Placebo  Controlled Clinical Trial of  SOM230 (Pasireotide LAR) In 
Severe Polycystic Liver Di sease.  
 
Principal Invest igator:   
Marie C. Hogan, MD, PhD 
Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN 55905. USA  
 
Co-Investigators:   Peter Brady , MB BCh , FRCP  
Ziad El -Zoghby, MD  
Bernard F. King, M.D.  
Tetyana Masyuk , PhD 
Vicente E. Torres , MD  PhD 
 
Statisticians:   
Eric Bergstralh , MS 
 Walter Kremers,MS 
 
  
Version numb er / date : 10/14/2014  
  
 Confidential  Page 2 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Table of contents  
Table of contents .......................................................................................................................2  
List of abbreviations .................................................................................................................5  
List of tables  ..............................................................................................................................6  
1 Introduction ...............................................................................................................................7  
1.1 Overview of Autosomal Dominant Polycystic Kidney and Liver Disease:..................7  
1.2 Background ...................................................................................................................7  
1.2.1  Somatostatin Analogs – the first medical therapy for PLD  ..........................7  
1.2.2  Pre-Clinical Studies with Somatostatin  ........................................................7  
1.3 Somatostatin analogs in the treatment of patients with PLD  ........................................7  
1.4 Pasireotide (SOM230)...................................................................................................8  
1.5 Clinical experience with pasir eotide .............................................................................8  
1.5.1  Pasireotide SQ  ..............................................................................................8  
1.5.2  Pasireotide LAR  .........................................................................................10  
2 Study Rationale/Purpose .........................................................................................................15  
2.1 Selection of doses........................................................................................................16  
2.2 Placebo dose ................................................................................................................16  
3 Objectives  ...............................................................................................................................16  
3.1 Primary objectives .......................................................................................................16  
3.2 Secondary objectives...................................................................................................16  
3.3 Tertiary objective  ........................................................................................................16  
4 Study design............................................................................................................................16  
4.1 Treatment  ....................................................................................................................17  
4.2 Follow-up ....................................................................................................................17  
4.3 Treatment extension  ....................................................................................................17  
5 Population ...............................................................................................................................17  
5.1 General criteria  ............................................................................................................17  
5.2 Inclusion/exclusion criteria  .........................................................................................18  
5.2.1  Inclusion criteria  .........................................................................................18  
5.2.2  Exclusion criteria  ........................................................................................18  
6 Treatment  ................................................................................................................................20  
6.1 Investigational and control drugs ................................................................................20  
6.1.1  SOM230C / Placebo  ...................................................................................20  
6.1.2  How supplied ..............................................................................................21  
6.1.3  Preparation and storage ..............................................................................21  
 Confidential  Page 3 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
6.1.4  Administration  ............................................................................................22  
6.2 Treatment arms  ...........................................................................................................22  
6.3 Patient numbering .......................................................................................................23  
6.4 Treatment blinding  ......................................................................................................23  
6.5 Pasireotide LAR dose adjustment  ...............................................................................24  
6.5.1  Permitted study drug adjustments  ..............................................................24  
6.6 Pasireotide LAR / placebo dose adjustment  ...............................................................24  
6.7 Concomitant therapy ...................................................................................................27  
6.8 Study drug discontinuation .........................................................................................27  
6.9 Premature patient withdrawal  .....................................................................................28  
6.10  Early Termination/E nd of treatment  ...........................................................................28  
7 Visit schedule and assessments  ..............................................................................................30  
7.1 Information to  be collected on screening failures  .......................................................31  
7.2 Patient demographics/other baseline characteristics  ...................................................31  
7.3 Treatments  ...................................................................................................................32  
7.4 Efficacy  .......................................................................................................................32  
7.4.1  Liver & total kidney volume, hepatic cyst volume, renal cyst volume ......32  
7.4.2  Treatment/Follow -up Decisions at Patient Evaluations .............................33  
7.5 Safety  ..........................................................................................................................33  
7.5.1  Adverse events............................................................................................34  
7.5.2  Vital signs  ...................................................................................................35  
7.5.3  Performance status ......................................................................................35  
7.5.4  Laboratory evaluations  ...............................................................................35  
7.6 Pharmacokinetics  ........................................................................................................37  
8 Other Safety Considerations: ..................................................................................................37  
8.1.2             Novartis instructions for rapid notification of serious adverse events .......41  Protoco         
10 Data management  ...................................................................................................................42  
10.1  Data collection  ............................................................................................................42  
10.2  Statistical methods  ......................................................................................................42  
11 References  ...............................................................................................................................43  
12 Appendices .............................................................................................................................45  
12.1  Appendix 1 Guidance for diarrhea management ........................................................45  
12.2  Appendix 2 Guidance for hyperglycemia management ..............................................48  
12.3  Appendix 3 Guideline for the treatment of QT prolongation .....................................51  
12.4  Appendix 4 SOM230 LFT Management Algorithm (s.c. and LAR Studies) .............54  
13 Procedures and instructions ....................................................................................................54  
 Confidential  Page 4 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
 
13.1.1  Publication of results ..................................................................................52  
13.1.2  Disclosure and confidentiality ....................................................................55  
13.1.3  Discontinuation of study .............................................................................55  
13.2  Ethics and Good Clinical Practice  ..............................................................................55  
13.2.1  Institutional Review Board/Independent Ethics Committee  ......................55  
13.2.2  Informed consent ........................................................................................55  
13.2.3  Declaration of Helsinki ...............................................................................54  
 
 Confidential  Page 5 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
List of abbreviations  
5-HIAA  Urinary 5 -hydroxyin dole acetic acid  
ACTH  Adrenocorticotropic Hormone  
AE Adverse Event  
ALT Alanine aminotransferase  
AST Aspartate aminotransferase  
b.i.d.  bis in diem /twice a day  
BG Blood Glucose  
CPO  Clinical Pharma Organization  
CRF Case Report/Record Form  
CRD  Clinica l Research and Development  
CRO  Contract Research Organization  
CS&E  Clinical Safety and Epidemiology  
CT Computer Tomography  
CTCAE  Common Toxicity Criteria for Adverse Events  
DM Diabetes Mellitus  
ECG  Electrocardiogram  
GCP  Good Clinical Practices  
GEP  Gastroenteropancreatic  
GH Glycosylated Hemoglobin  
GI Gastrointestinal  
GOT  Glutamic pxaloacetic transaminase  
GPT Glutamic pyruvic  transaminase  
HSST Human somatostatin receptor  
IB Investigator’s Brochure  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IM Intramuscular(ly)  
ITT Intent to Treat  
IV intravenous(ly)  
IRB Institutional Review Board  
IVRS  Interactive Voice Response System  
LAR Long Acting  Release  
MRI Magnetic Resonance Imaging  
MTD  Maximum tolerated dose  
o.d. omnia die /once a day  
PK/PD  Pharmacokinetic/Pharmacodynamic  
p.o. per os /by mouth/orally  
PRL Prolactin  
PT Prothrombin time  
PTT Partial thromboplastin time  
q.d. quaque die /every day 
REB Research Ethics Board  
SAE Serious Adverse Event  
SQ Subcutaneo us 
SRIF a Somatotropin release -inhibiting factor analog /somatostatin analogs  
SOP  Standard Operating Procedure  
SST Somatostatin  
TSH Thyroid Stimulating Hormone  
ULN Upper Limit Normal  
 
 Confidential  Page 6 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
List of tables  
Table 1  Binding profi le for octreotide and pasireotide at HSST1 -5 (IC50, M) ...8 
Table 2  Gross anatomy, cystic and fibrotic volumes, in PCK rats .....................14 
Table 3  Gross anatomy, cystic and fibrotic volumes, in Pkd2ws25 -/- mice  .....14 
Table 4  Handling and preparation of pasireotide LAR dose ............................223 
Table 5  Stratified randomization  ......................................................................224 
Table 6  Handling and preparation of pasireotide LAR different doses ............235 
Table 7  Guideline for treatment of patients experiencing adverse events  ........245 
Table 8  Visit evaluation schedule for patients receiving SOM230® ..................31 
Table 9  Core safety evaluation and frequency  .................................................313 
 
 Confidential  Page 7 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
1 Introduction  
1.1 Overview of Autosomal Dominant Polycystic Kidney and Liver Di sease:  
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal 
disease, affecting 1 in 400 to 1000 live births .1 ADPKD is caused by mutations in the PKD1  and 
PKD2  genes, and progresses to end -stage renal disease at a mean age of 55 years and 69 
years, respectively.1-3 Hepatic cysts are the most common extra -renal man ifestation of ADPKD 
and occur in the majority of these patients.4 Cysts increase with age and may cause consider a-
ble morbidity; including abdominal pain and distension, rupture, hemo rrhage, dyspnea, venous 
or biliary obstruction, and ascites. Some of these individuals are incapacitated due to massive 
polycystic liver disease (PLD). With increased lifespans due to dialysis and kidney transplanta-
tion, more patients with ADPKD develop severely symptomatic PLD . There are also patients 
with PLD without kidney disease due to mutations in different genes, some who  develop severe 
incapacitating liver disease.5,6 
1.2 Background 
1.2.1  Somatostatin Analogs – the first medical therapy for PLD  
Somatostatin (SST) analogs are the first medical therapy that have  been demonstrated to be e f-
fective in reducing liver volume and improving quality of life in treated individuals with PLD. SST  
may blunt cyst development by  acting at multiple levels: inhibition of secretin released by the 
pancreas ;7 inhibition of secretin- induced cAMP generation and fluid secretion in cholangi o-
cytes ;8-10 vasopressin- induced cAMP generation and water permeability in collecting ducts by its 
effects on G I protein- coupled receptors;11-14 and suppression of the expression of IGF- 1, vasc u-
lar endothelial growth factor, and other cystogenic growth factors and of downstream signal ing 
from their receptors.  
1.2.2  Pre-Clinical Studies wit h Somatostatin  
We have previously tested the effect of cAMP inhibition with the SST analog octreotide in an an-
imal model of PKD , the PCK rat , and observed a reduction in liver and kidney weight, cyst vol-
ume, fibrosis & cell proliferation.15 
1.3 Somatostatin analogs in the treatment of patients with PLD  
In clinical trials SST  analogs retard progression of PLD with up to one year of  treat ment.16-19 
Octreotide therapy also maintained the reduction in liver volume over two years in the O c-
treotide LAR treated group, while it did not increase significantly during Year 2 (Δ% -5.96 
±8.90%; p =0.002) in our small study.20 Furthermore, using pooled analys es of all individuals 
who received Octreotide LAR depot® (OctLAR®) for 12 months (n=40, in years one or two), the 
cumulative r eduction in liver volume was - 6.08% ±7.58% (p=0.001) compared to a net growth of 
0.9±8.35% in the historical placebo treated group.21 
While Oct LAR stimulates distinct SST  receptors  – SSTr 2, 3 and 5, all five receptor subtypes 
are expressed in rat and human and mouse cholangiocytes. Pasireotide (SOM230) exhibits high affinity binding to four of the five known human SST (HSST) receptors (SSTr 1-5) and binds with 
a 30 to 40 fold higher affinity than octreotide to the SST 1 and -5 receptor subtypes with a fiv e-
fold higher affinity to SST 3. Because of the broader SST  binding profile of pasireo tide, and the 
 Confidential  Page 8 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
known SST receptor subtype expression in liver tissue, pasireotide has the potential to be more 
effective than preferential SST 2 receptor - binding SST  analogs. Therefore we hypothesized that 
the pharmacological targeting of cAMP by pasiroetide will be even more effective than 
cctreotide in inhibiting cAMP levels, in decreasing the rate of cell proliferation and reducing 
hepato- renal cyst ogenesis.  
1.4 Pasireotide (SOM230)  
Pasireotide is an injectable SST  analog. It is a novel cyclohexapeptide with the following chem i-
cal name: (2- Aminoethyl)carbamic acid (2R, 5S,8S,11S,14R,17S,19aS) -11-(4-aminobutyl) -5-
benzyl -8-(4-benzyloxybenzyl) -14-(1H-indol -3-ylmethyl) -4,7,10,13,16,19 -hexaoxo -17-
phenyloctadecahydro- 3a,6,9,12,15,18- hexaazacyclopentacyclooctadecen-2- yl ester, di[(S) -2-
aminosuccinic acid] salt.  
Like natural SST  and other SST  analogs (SRIFa), pasireotide exerts its pharm acological activity 
via binding to SST receptors . There are five known SST receptors : SST 1, 2, 3, 4 and 5. SST  
receptors are expressed in different tissues under normal physiological conditions. SST  analogs  
activate these receptors with different potencies22 and this activation results in a reduced cell u-
lar activity and inhibition of hormone secretion. Sst  receptors are strongly expressed in many 
solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted 
e.g. acromegaly23 GEP/NET tumors24 and Cushing’s di sease.  
The SRIF s currently approved for use in the clinic (octreotide and lanreotide) have a high affinity 
to the SST subtype 2 ( SST2) receptor , with moderate or no a ffinity to the rema ining subtypes. 
Pasireotide is a novel cyclohexapeptide SST  analog that exhibits a unique binding profile, bind-
ing with high affinity to four of the five known HSST  receptors (Table 1). Compared to Sando-
statin® (octre otide acetate), pasireotide exhibits a binding affinity, which is 30- 40 times higher for 
HSST 1 and HSST5, 5 times higher for HSST 3, and 2.5 times lower for HSST 2 receptor . A de-
tailed summary of available preclinical data is provided in the Investigators' Br ochure.  
Additionally, preclinical studies suggest anti -tumor activity of SOM230. SOM230 has been found 
to significantly reduce cell proliferation of the neuroendocrine tumor cell line NCI -H727, whereas 
the conventional analog  SMS 201- 995 did not .25 
Table 1 Binding profile for octreotide and pasireotide at HSST 1-5 (IC50, M)  
Compound  SST1 SST2 SST3 SST4 SST5 
Octreotide  acetate  (SMS 201 -995) 2.8x10-7 3.8x10-10 7.1x10-9 >10-6 6.3x10-9 
Pasireotide  (SDZ 227 -230) 9.3x10-9 1.0x10-9 1.5x10-9 >10-6 1.6x10-10 
Ratio of IC 50:octreotide acetate  / pasireotide  SMS/SOM230  30 0.4 5 -- 40 
1.5 Clinical experience with pasireotide  
Pasireotide is available as a short -acting subcutaneous ( SQ) formulation and a long acting r e-
lease (LAR)  intramuscular (IM) formula tion. 
1.5.1  Pasireotide SQ 
Single dose of pasireotide SQ up to 1500 μg q.d. and 750 μg b.i.d. multiple SQ doses (7- 14 
days) up to 1500 μg q.d., 750 μg b.i.d. and 2100 μg b.i.d. (up to 5 days), and continuous (7 -day) 
SQ infusion by insulin pump, have been well -tolerated, with mostly mild, transient side effects 
reported. The most reported adverse events (AEs) were GI related (mild diarrhea and nau sea), 
requiring no treatment or study discontinuation. The frequency of these AEs appeared to de-
 Confidential  Page 9 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
crease with time in multiple- dose studies.  AEs were assessed using the NC I-CTC for A dverse 
Events, version 3.0 (CTCAEv3.0, [ http://ctep.cancer.gov/forms/CTCAEv3.pdf ]). 
Single and multiple doses of pasireotide SQ  have generally been well -tolerated by patients with 
acromeg aly, metast atic carcinoid tumor, or Cushing’s disease. Pasireotide has been studied in 
phase II studies at doses of up to 600 μg b.i.d. for acromegalic patients, 900 μg b.i.d. for p a-
tients with Cushing’s disease, and 1200 μg b.i.d. for patients with carcinoid tumors, with pasir e-
otide treatment periods of 4 years, 4.8 years and 1.6 years , respectively. For all these indic a-
tions the most frequent AEs are similar to what have been reported in healthy volunteers , 
predomi nantly mild diarrhea, nausea , and abdominal pain.  
Hyperglycemia was also observed across all indications. The effect on blood gl ucose was more 
pronounced in patients with Cushing’s disease, a setting in which glucose metabolism is inher-
ently dysregulated. The hyperglycemic effect in healthy volunteers (phase I study) is less pr o-
nounced when admini stered with a breakfast meal and appears to decrease after multiple doses 
indicating an attenuation of effect over time. The underlying mechanism of hyperglycemia fol-lowing pasireotide is thought to be due to the decrease in insulin secretory capacity with no e f-
fect on insulin sensitivity; however the effect of pasireotide on glucagon level is smaller. In phase II studies, fasting blood glucose increase tended to occur with increasing doses and ap-
peared t o be more notable in patients who had a history of hyperglycemia or diabetes mell itus, 
hypertension and hyperlipidemia prior to receiving pasireotide. Although hyperglycemia was fr e-
quently reported, few grade 3 or 4 AEs or SAEs or discontinuation due to AEs related hypergl y-
cemia were reported.  
Although no pre- clinical or clinical studies have revealed any specific pasireo tide-related cardiac 
toxicity issues, an effect of pasireotide on QTcF interval at 1950 μg SQ b.i.d. in healthy volun-
teers was demonstrated. The QTcF change from bas eline showed a peak effect at 2 -hour post -
dose of pasireotide SQ  was 17.5 ms ver sus placebo.  
1.5.1.1  Pasireotide LAR  
A total of 85 patients were enrolled in the [CSOM230C2110] study and received at least one dose of pasireotide ( SQ and/or LAR injection). Of these, 40 patients were diagnosed with acr o-
megaly and 45 with carcinoid tumors. Patients r eceived a single dose of 300 μg Pasireotide SQ 
followed by a washout period of at least 5 days.  Patients subsequently received 3 monthly ad-
ministration of pasireotide LAR IM . 
In patients with acromegaly, the most common AE overall and by treatment group was diarrhea affecting 12/35 patients in total, 3/10, 3/12 and 6/13 in the pasireo tide LAR 20 mg,  40 mg and 
60 mg group, respectively. Majority of the diarrhea were CTCAE grade 1 and none were  seri-
ous. Frequent AEs only reported in the 40 mg and 60 mg groups included abdominal disten sion, 
cholelithiasis, blood glucose increased, hyperglycemia and hematuria. All events but blood glu-
cose increased in the 40 mg group (2 patients) and hyperglycemia in the 60 mg group (3 pa-
tients) were observed for one patient in each of the two groups.  
In patients with carcinoid tumors, diarrhea was the most frequent AE affecting 4 patients in each treatment group (4/12 in the 20 mg group, 4/14 in the 40 mg group, and 4/16 in the 60 mg group). Diarrhea side -effects were of CTCAE grade 1 or 2 for all patients , except for one  patient 
in the pasireotide LAR 20 mg group , for wh ich the AE was reported as grade 3. Other frequently 
reported AEs were fatigue (9/42 patients), asthenia (5/42 patients), diabetes mellitus (6/42 pa-
tients), anorexia (5/42 patients), back pain (4/42 patients) and muscle spasms (3/42 pa tients). 
CTCAE grade 3 or 4 that were suspected to pasireotide LAR were primary hy perglycemia and 
 Confidential  Page 10 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
were reported in all dose groups. CTCAE grades 3/4 elevation of blood glucose level was r e-
ported in 18/42 (43%) patients. Median time to grades 3/4 elevation of blood glucose occu rred 
on day 1 of cycle 1 (range 1- 1131 days), approximately 6 hours (range 2- 8 hours) post -dose.  
Given the observed suppression of insulin secretion associated with pasireo tide administration, 
the use of insulin secretagogs and/or incretin- based therapies may be particularly suited for the 
treatment of pasireotide induced glucose dy sregulation.  
1.5.1.1.1  Clinical pharmacokinetics  
Pasireotide SQ and LAR have been studied in healthy volunteers, patients with acromegaly, 
Cushing’s disease and carcinoid syndrome. Followi ng a single IM  injection of 40 mg or 60 mg in 
healthy volunteers [CSOM230C2101], pasireotide LAR demonstrated a con trolled  release type 
of concentration- versus -time profile, with an initial spike phase on day 1 fol lowed by a slow -
release process for up to 42 days. The Cmax of the extended release phase was observed ap-
proximately on day 20 for both dose levels. Pasireotide LAR was also invest igated in patients 
with acromegaly and carcinoid tumors [CSOM230C2110]. Following monthly (q28 days) IM  in-
jections of 20, 40, or 60 mg pasireotide LAR, preliminary results showed an approximately linear 
dose- exposure proportionality and a steady state achieved following 3 injections. The PK expo-
sure to pasireotide at steady state in acromegalic patients was comparable to the sim ulated PK 
exposure at steady state in healthy volunteers, whereas, the PK exposure in patients with car-cinoid tumors was roughly 2- fold that in acromegalic patients.  
1.5.1.2  Phase II studies of pasireotide SQ in neuroendocrine tumors  
Preliminary safety data are available from a Phase II study [CSOM230B2202] in 45 patients with 
symptomatic metastatic carcinoid disease who received pasireo tide SQ doses from 300 µg SQ  
b.i.d. up to 1200 µg b.i.d. for a mean of 20 weeks. Overall pasireotide SQ  has been found to be 
generally well -tolerated by these patients, with the most common adverse events being mild di-
arrhea, nausea and abdominal pain. Blood glucose increases tended to occur with i ncreasing 
dose, but were moderate and generally managed easily by adjustment in oral hypoglycemic 
medications. Weight loss was also observed in 18 patients. Maximum weight loss occurred wit h-
in 4-6 months on the study drug, with a stabilization of effect after approximately 6 months. 
There was no appa rent relationship between the weight loss and pasireotide dose.  
Preliminary efficacy data from this study also support that pasireotide is active in patients refrac-
tory/resistant to Sandostatin LAR, as partial or complete sym ptom control was observed in 12 of 
44 patients (27%). Complete res ponse was achieved in two patients at the pasireotide 600 µg 
SQ b.i.d. dose and one at the 900 µg SQ  b.i.d. dose. Nine patients achieved partial r esponse to 
treatment, three at each of the following doses: 600, 750, and 900 µg SQ b.i.d.  
1.5.2  Pasireotide LAR  
Most of the experience with pasireotide comes from healthy volunteer and patient studies eval-
uating the subcutaneous formulation of pasireotide. Pasireo tide LAR is being evaluated in two 
studies, one healthy volunteer study and one study involving patients with acromegaly and ca r-
cinoid disease.  
1.5.2.1  Pasireotide LAR in healthy volunteers 
Preliminary data from the healthy volunteer study found single IM doses of pasi reotide LAR, at 
doses of up to 40 mg and 60 mg, respectively , to be well -tolerated. The most common AEs 
 Confidential  Page 11 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
were gastrointestinal. Diarrhea was experienced by most of the subjects and was som etimes 
associated with abdominal pain, flatulence, and/or nausea. The gastrointestinal events were 
mild or mo derate in severity. About 38% of subjects reported mild inject ion site pain and about 
15% reported headaches. 
Transient elevations in liver function tests and/or pancreatic enzymes were ob served in three 
subjects, all of which resolved and were not accompanied by any clinical symptoms. Mild i n-
creases in fasting blood glucose were observed in some subjects during the pasireotide LAR 
treatment period.  All elevations were asymptomatic, considered not clinically significant , and 
generally r eturned to normal within 3- 4 weeks after the pasireotide LAR IM injection.  
1.5.2.1.1  Serious adverse events 
A cumulative search (data lock point 12 Oct 2011) of the Novartis safety database was per-
formed using MedDRA 14.0 on SMQ “ Drug related hepatic disorders – comprehensive search. ” 
This search retrieved one serious case of i ncreased liver enzymes which meets Hy’s law criteria 
in a young female patient with Cushing’s disease who appeared jaundiced and fully recovered upon discontinuation of pasireotide. Nine days after the start of pasireotide the laboratory val ues 
were as follows: total bilirubin 94 μ mol/l (3.9x  ULN), ALP 157 U/L (1.4x  ULN), ALT 568 U/L 
(10.3x  ULN), AST 251 U/L (5.6x  ULN), and lactate de hydrogenase 300 U/L (1.3x  ULN). All liver 
function tests were within normal limits 45 days after discontinua tion of pasireotide. This report 
was released as an Investigator notification in September 2010, with follow -up Investigator n oti-
fications in October 2010 and May 2011 (PHHO2010AU13717).  
1.5.2.1.2  Liver safety analysis of studies conducted with pasireotide–p hase I -III studi es 
A review of the unblinded data from the clinical program with the pasireotide LAR formulation 
did not reveal cases meeting the Hy’s law criteria. Across the clinical devel opment program with 
pasireotide SQ to date: 
654 healthy volunteers have been exposed to pasireotide SQ: 
3 (0.5% ) met the biochemical criteria of Hy's law (see details above)  
16 (2.4%) subjects had an ALT/AST > 3x , < 5x ULN  
3 (0.5%) of the subjects had an ALT/AST > 5x  ULN 
17 (2.6%) subjects had a total bilirubin of 2x  ULN (including 7 patients with pre -existing live r 
disease and elevations of total bilirubin); 
156 patients in phase 1 and phase 2 trials have been exposed to pasireotide SQ : 
None of the patients met the biochemical criteria of Hy's law  
6 (3.8%) patients had an ALT/AST > 3x , < 5x ULN 
4 (2.6%) patients had an ALT/AST > 5x  ULN 
2 (1.3%) patients had a total bilirubin of 2x  ULN; 
162 patients with Cushing’s disease in phase 3 trials have been exposed to pasireotide SQ : 
None of the patients met the biochemical criteria of Hy's law  
8 (4.9%) patients had an ALT/A ST > 3x , < 5x  ULN 
1 (0.6%) patients had an ALT/AST > 5x ULN  
 Confidential  Page 12 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
None of the patients out of 162 with Cushing’s disease had a total bilirubin of  2x ULN. 
Approximately 200 patients in the compassionate use program have been exposed to pasir e-
otide SQ to date. There was one serious case of a patient with Cushing's disease who met the 
biochemical criteria for Hy's law. This case (PHHO2010AU13717) is discussed above. (See I n-
vestigator Notification for pasireotide [ SOM230] October 31, 2011)  
 
Novartis released an Investigator Notification dated 31 Oct 2011 that provided updated infor-
mation regarding reversible liver chemistry elevations in 3 healthy volunteer subjects meeting the biochemical criteria for Hy’s Law in two cases and potentially meeting Hy’s Law criteria i n 
one case (missing ALP value and confounding concomitant medication). All three cases were asymptomatic and reversible and the degree of the increase in aminotransferase levels was < 
4x ULN. The investigators did not consider the laboratory abnormalities in healthy volunteers as 
adverse events and consequently did not report them as such.  
While Novartis considers the risk -benefit ratio for SOM230 to remain positive, they are impl e-
menting the following urgent safety measures by means of this communication to ensure the safety of patients .  
For studies with ongoing enrollment using the LAR formulation: Liver function tests (LFTs) must be assessed at screening, baseline, Day 22 after the first injection, Day 29, Day 50, Day 57 and Day 85. After Day 85, monitoring should follow the existing protocol schedule. The Day 22 and 
Day 50 LFTs must be available and assessed prior to dosing on Day 29 (2nd injection) and Day 
57 (3rd LAR injection).  For studies with ongoing enrollment using s.c. or LAR formulation: R e-
vised exclusion criteria for LFTs ( Table 1 ).  
For all ongoing studies: Additional hepatic management (i.e. liver -directed history and phys ical 
examination, LFTs, hepatitis screen, abdominal ultrasound, and PK sample) is to be implement-ed within 72 hours of awareness of abnormal liver function tests. Follow -up LFT monitoring will 
take place at 3- 4 day intervals for all s.c.  and LAR studies ( Table 2).  
For all ongoing studies: Additional LFT discontinuation criteria are to be implemented (Table 7).  
An algorithm of LFT management for all SOM230 s.c. and LAR studies is provided in appendix 
4. 
1.5.2.2  Pasireotide LAR in PLD patients  
Preclinical studies in the PCK rat (a recessive model of polycystic kidney and liver disease) 
showed that the SST analog oc treotide reduces cAM P levels in kidney and bile ducts and slows 
the progression of hepato- renal cystogenesis.
15 We previously completed a double- blinded, 
randomized, pl acebo- control led clinical trial ([STUDY_ID_REMOVED]) using  OctLAR over 1 year in forty -
two patients with severe polycystic liver disease (PLD), due to autosomal dom inant polycystic 
liver disease (ADPLD) or autosomal dominant polycystic kidney disease (ADPKD).  By ma gnetic 
resonance imaging, the mean liver volume de creased from 5907 to 5557 ml (4.95 ±7.00%) in 
the octreotide group (n = 28) compared with 5374 to 5361 ml (0.92 ±_7.00%) in the placebo group ( n =14). This diffe rence (mean 4.95 versus 0.92%) was significant ( P= 0.045 ). The self -
reported SF- 36 quality of life form demonstrated a significant improvement in percep tion of body 
pain and physical function in octreotide -treated patients.
18 Moreover, three sepa rate prospective 
clinical trials have now shown similar positive effects of SST  analogs in ADPLD and ADPKD.16-
19,26 A few other published reports relating to the use of SST  analogs further substantiate these 
observations .17,26-28 All of these studies were li mited by small numbers of enrolled patients with a 
 Confidential  Page 13 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
short follow -up of 6 -12 months. In order to evaluate whether SST  analog therapy sustains reta r-
dation of liver and kidney growth beyond one year, our protocol design included a second year 
of open -label active therapy with OctLAR. We completed an open- label extension with OctLAR 
for 1 addi tional year, to assess safety & clinical benefits over 2 years (O→O) and examine drug 
effect s in the placebo group who crossed over to OctLAR in y ear 2 (P→O).21 The primary end-
point was a change in total liver volume (TLV); secondary endpoints were changes in total ki d-
ney volume (TKV), glomerular f iltration rate (GFR), quality of life (QOL), safety, vital signs, & lab 
parameters. Forty -one of 42 patients that received OctLAR (n=28) or placebo (n=14) in year 1 
received OctLAR in year 2 (max dose 40 mg). Patients originally randomized to placebo (P→O)  
showed substantial reduction in TLV after treatment with OctLAR in year 2 ( -7.66±9.69%; p= 
0.011). The initial reduction of TLV in the OctLAR group (O→O) was mai ntained for 2 years ( -
5.96± 8.90%), although it did not change significantly during year 2 ( -0.77±6.82%). OctLAR i n-
hibited renal enlargement during year 1 (+0.42±7.61%), but not throughout year 2 in the O→O group (+6.49±7.08%) ; and in the P→O group in year 2 ( -0.41±9.45%). U sing pooled analyses of 
all individuals who received OctLAR for 12 months ( n=40; in years 1 & 2), reduction in TLV was 
-6.08%±7.58% (p=0.001) com pared to net growth of 0.9±8.35% in the (P→O) group.  
Changes in GFR were similar in both groups. Over 2 years OctLAR significantly reduced the 
rate of increase in TLV and  possibly the rate of increase in TKV. While OctLAR inhibited renal 
enlargement within the first year of treatment, it a ppeared to lose effectiveness during year 2. 
Several reasons may account for the reduction of effect seen in year 2. First, SST  receptors 
may undergo receptor down- regulation / desensitization (probably by endocytosis of the recep-
tor-ligand complexes) after prolonged exposure to OctLAR.
29-31 Second, we did not monitor 
OctLAR levels in plasma, its metabolism, cAMP concentration, or whether levels of the effectors 
IGF, GH, or EGF were modulated by therapy. In the pre -clinical animal studies, liver and kidney 
effects were dose- dependent, therefore higher doses of SST  analogs may be required.15 Third, 
OctLAR is known to bind to three out of five known SSTs (SST2 , SST3  and SST5) . At this point, 
we do not know what  SST receptor s are present in liver and kidneys of our patients, and how 
their expression is different from normal hepatic  and renal epithelia. Thus, the use of more po-
tent SST analogs (e.g. SOM230, pasireotide) that bind to a broader range of SST  receptors 
might be mo re efficient  (figure 1). This treatment if successful  could impact greatly on quality of 
life and decrease morbidity and mortality related to PLD in these patients. A subset of individu-als is incapacitated due to massive PLD and the numbers of  patients in this subset are steadily 
increasing, due to i ncreased lifespan because of dialysis and kidney transplantation. This study 
will evaluate the effect of SOM230 LAR
® on the liver volumes of patients with severe PLD who 
are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection 
or liver transplantation and therefore have no further therapeutic op tions.  
1.5.2.2.1  Pre- Clinical Studies with Pasireotide in PLD  
Dr. Masyuk (Mayo Clinic) has recently completed comparative studies of octr eotide and pasir e-
otide and shown that pasireotide decreased hepatorenal cystic and fibrotic volumes in PCK rats 
and Pkd2ws25/ - mice . She found in all experiments that the effects of pasireotide were signif i-
cantly greater compared to octreotide – see Tables  2 and  3.32 
 Confidential  Page 14 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Table 2 Gross anatomy, cystic and fibrotic volumes, in PCK rats  
In the PCK rat model of PLD, liver weight decreased by 27.7% in males and 23.9% in females 
and cyst volume decreased by 41.7% compared with controls. Renal cyst volume de creased by 
30.4% compared with controls (p 0.0001). In a second animal model Pkd2ws25/ - mice ( Table 
3), liver weight decreased by 26% compared with controls (p=0.05),  hepatic cystic areas de-
creased by 44.1% compared with controls (p=0.0007). Hepatic fibrotic area decreased by 
35.6% com pared with controls (p=0.0001).  Renal cystic area decreased by 35.6% on pasir e-
otide compared to controls (p=0.0001). In primary cultures of normal and rat cholangiocytes,  
pasireotide was more effective in reducing proliferation of PCK cholangiocytes and growth of normal cholangiocytes (p<0.05, compared with octreotide) and also in reducing cyst growth in 
primary (3D) cell culture (p<0.05 compared with o ctreotide)  (Figure 1) . Therefore these pre-
clinical data provide strong justification for further clinical evaluation of the effects of pasireotide in individuals with polycystic liver and kidney di sease.  Parameters Control  OCT  PAS OCT vs co ntrol PAS vs control  OCT vs PAS  
p %  
change  p % 
change  p % 
change  
Body wt (g):  
 Male  
 Female  430.3±22.9  
253.7±6.57  411.8±8.93  
244.0±6.54  371.6±6.11  
232.8±12.86  NS 
NS -4.3 
-3.8 0.003  
0.05 -13.6  
-8.2 0.006  
NS -9.8 
-4.6 
Liver wt (g):  
 Male  
 Female 27.20±1.59  
18.63±0.42  23.60±0.83  
16.10±0.71  19.36±1.17  
14.17±0.54  0.02 
0.05 -13.2  
-13.6  0.003  
0.009  -27.7  
-23.9  0.001  
0.05 -16.6  
-12.0  
Liver wt  
(% bw):  
 Male  
 Female  6.32±0.11  
7.35±0.17  5.74±0.18  
6.59±0.18  5.30±0.14  
6.07±0.11  0.01 
0.03 -9.2 
-10.4 0.002  
0.003  -16.2  
-17.4 0.02 
0.04 -7.7 
-7.8 
Kidney wt (g): 
 Male  
 Fema le 6.27±0.16  
4.20±0.17  5.60±0.16  
3.75±0.11  4.82±0.11  
3.33±0.10  0.01 
0.03 -10.6  
-10.7 0.001  
0.001  -23.1  
-20.6 0.003  
0.01 -13.9  
-11.1 
Kidney wt  
(% bw):  
 Male  
 Female  1.47±0.12  
1.66±0.05  1.36±0.09  
1.54±0.08  1.30±0.08  
1.44±0.05  0.01 
0.008  -6.6 
-7.3 0.001  
0.04 -11.3  
-12.8 0.05 
0.006  -5.0 
-5.9 
Hepatic cystic 
volume 12.20±1.67  9.22±1.75  7.11±1.11  0.0001  -24.4  0.0001  -41.7  0.0001  -22.9  
Hepatic f ibrotic 
volume 7.55±0.56  6.74±0.34  6.11±0.39  0.05 -10.9  0.002  -19.3  0.05 -9.4 
Renal cystic vol-
ume 17.23±1.62  13.48±1.33 11.99±1.28  0.0001  -21.7  0.0001  -30.4  0.0001  -11.06  
Renal f ibrotic 
volume 2.68±0.11  2.22±0.15  2.07±0.14  0.001  -17.3  0.001  -22.9  0.04 -6.7 
 Confidential  Page 15 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Table 3 Gross anatomy, cystic and fibrotic volumes, in Pkd2ws25 -/- mice   
 
 
2 Study R ationale/ Purpose 
Pasireotide (SOM230) is a novel multi- receptor -targeted analog that has high af finity for four of 
the five SST receptor subtypes ( SSTr1, SSTr2, SSTr3 and SST r5);22 33 33 it has a 40 -fold higher 
affinity and 158 -fold higher functional activ ity for the SST 5 receptor  than octreotide. Because of 
its broad receptor binding profile, pasireotide may be more potent in PLD than octreotide. In this 
randomized double blind placebo controlled trial we will compare SOM230 treatment to pl acebo 
for 12 months in patients with PLD. The primary endpoints will be assessed at 12 months and 
patients receiving placebo then crossed over to SOM230, permitting all participants to receive 
SOM230 for the subs equent two years. MRI will be used to assess liver volume – the primary 
endpoint, which will be assessed at baseline, end of years 1 and 3. This study will assess the 
efficacy and safety of SOM230 in reducing total liver volume and improving quality of life over 12 months (we will not be assessing efficacy at 24 months. The therapy way be e ffective in PLD 
but also may prove to be effective for many more patients with PKD which will be evaluated us-ing eGFR and kidney vol ume using MRI.  Parameters Control  OCT  PAS OCT vs co ntrol PAS vs control  OCT vs PAS  
p %  
change  p % 
change  p % 
change  
Body wt (g):  31.60±3.57  33.76±2.49  33.92±1.53  NS 6.8 NS 7.3 NS 0.5 
Liver wt (g):  3.60±0.47  2.76±0.18  2.65±0.12  0.05 -23.3 0.05 -26.4 NS -3.9 
Liver wt  (% bw):  11.57±1.21  8.35±0.73  7.62±0.53  0.02 -27.9 0.01 -34.1 NS -8.7 
Kidney wt (g): 0.65±0.09  0.56±0.04  0.55±0.06  NS -13.5 NS -14.2 NS -0.8 
Kidney wt  (% bw):  2.08±0.14  1.69±0.11  1.59±0.08  0.03 -18.6  0.008  -23.7  NS -6.2 
Hepatic cystic a r-
ea 41.55±4.73  29.75±2.53  23.24±1.16  0.03 -28.4  0.0007  -44.1  0.03 -21.9  
Hepatic f ibrotic 
area 2.29±0.16  1.77±0.12  1.39±0.09  0.02 -22.5  0.0001  -39.5  0.003  -21.7  
Renal cy stic area 31.83±2.85  23.69±2.15  20.24±1.99  0.002  -25.6 0.0001  -35.6 0.03 -13.5 
Renal f ibrotic area 1.49±0.11  1.23±0.04  1.06±0.06  0.0006  -18.0 0.0001 -29.5 0.003  -14.1 
Figure 1:  Role of octreotide (OCT) 
and Pasireotide (PAS) treatment in 
hepatic cystogenesis. Our exper i-
mental data suggest that ex pression 
of SSTR1, 2 and som atostatin level 
are decreased in cystic cholangi o-
cytes that results in cAMP elevation 
and activation of the cellular pro-
cesses involved in hepatic cystoge n-
esis.  Ho wever, the expression of 
SSTR3, 4 and 5 did not change. Thus, treatment of cystic cholangi o-
cytes with OCT (binds to SSTR2, 3 
and 5) or PAS (binds to SSTR1, 2,3 
and 5) should lead to cAMP inhibi tion 
and decreased growth of hepatic 
cysts. 
 Confidential  Page 16 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
2.1 Selection of doses  
Patients will be treated with SOM -230 (pasireotide LAR) 60mg IM once every 28 days or plac e-
bo year 0- 1. All participants will receive pasireotide LAR years 2 and 3. Each cycle is 28 ± 2 
days. There will be no dose titration above the 60mg dose but there may be dose reduction to 
20mg if patients do not tolerate 60mg  or 40mg . 
2.2 Placebo dose  
The placebo dose will be monitored and adjusted monthly in a similar fas hion.  
3 Objectives 
3.1 Primary objectives  
The primary objectives of this study will be to evaluate the absolute and percent changes in liver 
volume from baseline to month 12 in the treatment arm co mpared to the placebo arm.  We will 
also evaluate the adverse events throughout the length of the study  and as reported at  12 and 
36 months of treat ment . 
3.2 Secondary objectives  
Absolute and percent changes in liver volume in the placebo group before (year 1) and after (years 2- 3) cross -over to active treatment  
Absolute and percent changes in liver volume in the treatment arm during years 2- 3 compared 
to the placebo arm during year 1  
Changes in eGFR from baseline (or from month 3) at 12 and 36 months in individuals with 
ADPKD  
Changes in k idney volume from baseline at 12 and 36 months in individu als with ADPKD  
Symptoms at baseline, 12 and 36 months. Changes in symptoms, measured by SF36-
questionnaire QOL -questionnaire 
Quality of Life at b aseline,12 and 36 months. Changes in quality of life, measured by SF36-
questionnaire (
SF-36v2™)  
Responders at 12 and 36 months.  
3.3 Tertiary objective  
Longitudinal changes beyond 12 months in above factors, stratified by treatment s equence.  
4 Study design 
This study will be conducted over 3 years as a randomized, double- blind control, clinical trial 
through year 1, followed by an open- label extension phase for the subsequent 2 years. S creen-
ing and randomization visits will take place at Mayo Clinic and patients will then be followed by Mayo Clinic for three years.  We will monitor the patients with blood and urine tests on days 22, 
29, 50, 57 and 89 and then at Months 6,9, 12, 15, 18, 24, 27, 30, 33 and 36.  Follow up visits will 
occur at one and three months post last dose of study drug. For patients who received pl acebo 
during year one, the labs on days 22,29,50,27 and 85 will be repeated as these are safety labs.  
All patients will be required to undergo MRI or CT scan imaging at the baseline, 12 month (end 
 Confidential  Page 17 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
of year 1) and 36 month (end of year 3) visits to fulfill the  primary study endpoints. Safety moni-
toring with ECG, Hemoglobin A1C , liver function and glucose testing will be performed l ocally at 
the study sub- sites and monitored cen trally by study staff at Mayo Clinic.  
 
Patients will be recruited during visits to the Department of Nephrology and Hypertension 
 
Patients who had participated in previous studies will also be contacted as long as they meet all 
eligibility criteria. We will also recruit through clinicaltrials.gov ( http://clinicaltrials.gov  ), Mayo 
Clinic Trials website ( http://clinicaltrials.mayo.edu/  ) and PKD  foundation clinical trials   ( 
http://www.pkdcure.org/Research/ClinicalTrials/ActiveRecruiting.aspx  )listed on the web .  P a-
tients who contact the study coordinator will be given information regarding the study and parti c-
ipation.  The study coordinator will screen those interested and proceed with the study design for all patients who would like to participate.  
  
4.1 Treatment  
Forty -eight patients with severe PLD identified at a single Center, Mayo Clinic, Rochester, MN 
will be stratified with randomization in a 2:1 allocation to  SOM230 or placebo in year 1, in this 
study. All participants will be offered SOM230 in years 2 and 3. Recruitment of patients is ex-
pected to occur rel atively rapidly (over the first 6 months) as a result of the Mayo Clinic’s large 
referral  base for patients with ADPKD and ADPLD and we have more than 140 patients  who 
wish to be notified if clinical trials with SST  analogs for PLD become available.  
4.2 Follow -up 
Follow up will continue until 3 months after last injection to monitor hemogl obin A1C.  
4.3 Treatment ext ension  
No further treatment extension is planned beyond the three years of this prot ocol. 
5 Population  
5.1 General criteria  
A total of 48 patients (45 + 3 to allow for dropouts) with severe PLD with either autosomal dom i-
nant polycystic kidney (ADPKD) or autosomal dominant liver disease (ADPLD) will be enrolled. 
To enroll a patient, call . Study personnel will check patient el-
igibility and the existence of a signed consent form before treat ment is begun.  
Limited T ravel reimbursement  is provided. Costs of tests obtained for the sole purpose of this 
study will be defrayed from study funds. Costs of tests necessary for pa tient's usual evaluation 
and management will be borne by patient and his/her health coverage. Pasir eotide- LAR safet y 
data, the absence of other medical treatment modalities for this group of patients, and prelim i-
nary ex perimental and clinical observations justify such a study. Patients must meet all criteria 
listed below. The investigator or her designee must ensure that all patients who are offered en-
rollment in the study meet all of the following inclusion and exclusion criteria. This will be a si n-
gle ce nter study at Mayo Clinic, Rochester, MN.  

 Confidential  Page 18 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
5.2 Inclusion/exclusion criteria  
The investigator or her designee must ensure that all patients who are offered en rollment in the 
study meet all of the following inclusion and exclusion crit eria: 
5.2.1  Inclusion criteria  
Male or female Age ≥ 18 years.  
Diagnosis of PLD associated with ADPKD (meeting the Modified Ravine’s criteria)34 or isolated 
ADPLD (defined by the criteria described by Reynolds et al )35.  
Severe PLD defined as a liver volume >4000mL or symptomatic disease due to mass effects 
from hepatic cysts (must be able to undergo MRI or CT scan to deter mine this).  
Not a candidate for or declining surgical intervention.  
Capable of providing informed consent.  
Life expectancy ≥ 12 weeks  
Patients with a known history of impaired fasting blood glucose (glucose >100 and <126) may be included at the discretion of the PI. These patients should be monitored closely throughout 
the trial and anti -hyperglycemic treatment adjusted as necessary. Patients that are deemed non 
eligible due to elevated glucose can be re- screened after adequate medical trea tment.  
Adequate end organ function as defined by: 
Adequate bone marrow function:  
• WBC ≥ 2.5 x 10
9/L 
• Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L  
• Platelets ≥ 100 x 109/L  
• Hb ≥ 9 g/dL  
No evidence of significant liver disease:  
• Serum bilirubin ≤1.5 x ULN 
• INR < 1.3  
• ALT and AST ≤ 2 x ULN  
Estimated glomerular filtration rate (eGFR) >30 ml/min/m2  
Serum amylase and lipase ≤ 1.5 x ULN  
Alkaline phosphatase ≤ 2.5 x ULN  
Written informed consent obtained prior to any screening procedures  
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and 
other study procedures  
5.2.2  Exclusion criteria  
Patients will be considered ineligible for this study if they meet any of the following crit eria: 
Patients with a known hypersensitivity to SST  analogs or any component of the pasireotide LAR 
or SQ formulations.  
 Confidential  Page 19 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Patients with known malabsorption syndrome, short bowel or chologenic diarrhea not con trolled 
by specific therapeutic means.  
Patients with abnormal coagulation (PT or a  PTT elevated by 30% above normal li mits). 
Patients on continuous anticoagulation therapy. Patients who were on anticoagulant therapy 
must complete a washout period of at least 10 days and have confirmed normal coagulation pa-
rameters before study incl usion.  
Patients with symptomatic cholelithiasis.  
Patients who are not biochemically euthyroid.  
Patients with known history of hypothyroidism are eligible if they are on adequate and stable r e-
placement thyroid hormone therapy for at least 3 months.  
Serum magnesium ≥ ULN  
QT-related exclusion criteria:  
QTcF at screening > 470 msec  
Patients with a history of syncope or family history of idiopathic sudden death  
Patients who have sustained or clinically significant cardiac arrhythmias  
Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, 
clinically significant/symptomatic bradycardia, or high -grade AV block   
Patients with concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or 
cardiac failure  
Family history of long QT syndrome  
Concomitant medications known to prolong the QT interval.  
Potassium < or = to 3.5  
Patients who have any severe and/or  uncontrolled medical conditions or other conditions that 
could affect their participation in the study such as:  
Patients who have Uncontrolled diabetes as defined by HbA1c>8%* despite adequate therapy  
Patients with the presence of active or suspected acute or chronic uncon trolled infection or with 
a history of immunodeficiency, including a positive HIV test result (ELISA and Western blot). An 
HIV test will not be required; however, previous medical history will be reviewed.  
Non-malignant medical illnesses that are uncontrolled or whose control may be jeopar dized by 
the treatment with this study treatment.  
Liver disease such as cirrhosis, decompensated liver disease, chronic ac tive hepatitis or chronic 
persistent hepatitis.  
Baseline ALT or AST >3x ULN  
Patients with l ife-threatening autoimmune and ischemic disorders. 
Uncontrolled hypertension 
Patients who have a history of a primary malignancy, with the exception of locally ex cised non-
melanoma skin cancer and carcinoma in situ of uterine cervix. ( Patients who have had no ev i-
 Confidential  Page 20 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
dence of disease from primary cancer for 3 or more years are allowed to participate in the 
study. ) 
History of pancreatitis  
Patients with a known history of hepatitis B or C  
Presence of Hepatitis B surface antigen (HbsAg)  
Presence of Hepatitis C antibody (anti -HCV)  
Patients with a history of, or current, alcohol misuse/abuse within the past 12 months  
Known gallbladder or bile duct disease, acute or chronic pancreatitis  
Patients who have any current or prior medical condition that may interfere with the con duct of 
the study or the evaluation of its results in the opinion of the Investigator or the Sponsor’s Medi-
cal Monitor  
Use of an investigational drug within 1 month prior to dosing 
Patients with a history of non- compliance to medical regimens  or who are considered poten tially 
unreliable or will not be able to complete the entire study  
Females who are pregnant or lactating, or are of childbearing potential (defined as all women 
physiologically capable of becoming pregnant) and not practicing an effective method of contr a-
ception/birth control.  Sexually active males must use a condom during intercourse while taking 
the drug and for 2 months after the last dose of the study drug and should not father a child in 
this period. A condom is required to be used also by vasectomized men in order to prevent de-
livery of the drug via seminal fluid. Effective contraception methods i nclude:  
Use of oral, injected or implanted hormonal methods of contraception   
Placement of an intrauterine device (IUD) or intrauterine system (IUS)  
Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) 
with spermicidal foam/gel/film/cream/ vaginal suppos itory  
Total abstinence or  
Patient sterilization (male or female)  
6 Treatment  
6.1 Investigational and control drugs   
6.1.1  SOM230C  / Placebo  
Pasireotide LAR (long- acting release) IM depot injection: 
Inactive ingredients of pasireotide LAR include: mannitol, carmellose sodium (carboxymethyl-cellulose sodium), poloxamer 188 and water for injection. Inactive i ngredients of pasireotide SQ  
include: mannitol, tartaric acid, sodium hydroxide and water for injection. For detailed infor-
mation on pasireotide, please refer to Sections 1.3 and 1.4 o f the Pasireotide Investigator Br o-
chure.  
Placebo:  
The placebo will have an appearance similar to SOM230.  
 Confidential  Page 21 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
6.1.2  How supplied  
Pasireotide LAR IM depot injections will be supplied in open- label packaging by Novartis as a 
powder in vials containing 20 mg , 40 mg and 60 mg labeled as SOM230 LAR or pl acebo, with 
ampoules containing 2mL of vehicle (for reconstitution).  
No syringes or needles will be pr ovided with the pasireotide study drug supplies.  
The p lacebo will be supplied (as powder) for mixing with injection solution by N ovartis.  
6.1.3  Preparation and storage 
Prior to reconstitution, vials should be brought to room temperature. Pasireotide LAR should 
then be prepared as shown in Table 4.  
 Confidential  Page 22 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Table 4 Handling and preparation of pasireotide LAR dose 
Doses should be prepared and administered immediately after preparation.  For additional de-
tails regarding prepar ation, refe r to Appendix  4.  
Novartis will supply pasireotide LAR as long as the patient remains on study, shows continuous 
benefit from treatment, and there are no safety concerns. Medication labels will comply with the 
legal requirements of the U.S. and will be printed in English. The storage conditions for pasir e-
otide LAR will be described on the medication label. Bottles must be stored in a safe, secure l o-
cation.  
All study medication will be supplied to Mayo by Novartis.  Mayo Research Pharmacy will be r e-
sponsible for storage of medication .  An accurate record of the date and amount of study drug 
dispensed to each subject must be available for i nspection at any time.  
All drug supplies are to be used only for this protocol and not for any other purpose. Unless speci fically instructed by Novartis, the investigator must not de stroy any drug labels . All unused 
or damage drug will be sent to ALMAC Clinical Services . The storage condition for the study 
drug will be described on the medic ation label.  
6.1.4  Administration  
Pasireotide LAR/placebo will be administered IM intragluteally, every 4 weeks. The starting 
dose will be 60 mg. The reconstitution has to be performed just prior to administration of the 
suspension. A minimal standing time can be tolerated for the reconstituted suspension in the v i-
al. Prior to administration, the reconstituted suspension in the vial should be shaken again be-fore withdrawal in the syringe. The IM injection must be given immediately after withdrawal of 
the reconstituted suspension from the vial to the syringe.  
All dosages prescribed and dispensed to the patient and dose changes during the study must be recorded. The investigational study drugs used in the course of this trial are pasireotide LAR 
(SOM230C) / placebo. Novartis will supply pasireotide LA R and placebo free of charge for study 
participants.  
6.2 Treatment arms  
There will be stratified randomization for  PLD patients with ADPLD and ADPKD  (see T able 5) :  
All participants who receive the placebo during year one will be given the option to continue on study to receive active study  drug for years two and three. Thus, all participants will be r eceiv ing 
SOM230 years two and three.  
Table 5 Stratified randomization 
The initial assessment will be derived on a clinical 
basis as some i ndividuals with ADPLD also may 
have kidney cysts.  Dose  Volume to be injected  
20 mg  1 x 20 mg vial + 2 mL vehicle; whole volume to be injected  
40 mg  1 x 40 mg vial + 2 mL vehicle: whole volume to be injected  
60 mg  1 x 60 mg vial +  2 mL vehicle; whole volume to be injected  
Disease Group  SOM230  Placebo  
ADPLD  8 4 
ADPKD  24 12 
Total  32 16 
 Confidential  Page 23 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
6.3 Patient numbering  
Randomization numbers will be provided by the study statistician to Research Pha rmacy.  
The recommended blinding methods are as following: randomization data are kept strictly conf i-
dential until the time of treatment un -blinding. This information will not be accessible with the fol-
lowing exceptions: pharmacist , as needed for r econstitution; an independent biostatistician, who 
will perform the analysis or database lock ; the investigator and only immediately rel evant study 
staff after LPLV . The identity of the treatments will be concealed by the use of study trea tments 
that are all identical in packaging, labeling, schedule of administration and appearance after r e-
constitution. Once the last patient completes LPLV, the database will be cleaned and an interim 
or final database lock will be placed. Subsequently, the database will be unblinded to the inves-
tigator and the sponsor.  
6.4 Treatment blinding  
Pasir eotide LAR/ placebo will be administered IM every 28 ± 2 days in the clinic only by an un-
blinded study nurse. The current recommended starting doses for pasireotide LAR is 60 mg for 
NET and 40 mg or 20 mg for acromegaly.  
Medication labels for SOM230 LAR and placebo will comply with the US legal requirements. There will be no information about the patient provided on the study drug label.  
Study drug, SOM230 / placebo IM depot injections will be supplied by Novartis as a pow der in 
vials containing 20 mg , 40 m g and 60 mg labeled as SOM230 LAR or placebo, with ampoules 
containing 2mL of vehicle (for reconstitution).  
For this blinded study, patients, investigator, site personnel and data analysts will be blinded to 
the identity of the treatment from the time of r andomization until pr otocol specified schedule of 
un-blinding. An unblinded pharmacist or a study nurse identified prior to start of the study are to 
be the only site personnel to reconstitute the study drug.  
Un-blinding will only occur in the case of pat ient emergencies, after LPLV for the investigator 
only, and after final database lock (at end of year 1, and at end of year 3). Pasireotide LAR is to 
be stored in a secure locked area while under the responsibility of the investigator. An autho r-
ized person at the investigational site must record receipt and dispensation of the study medic a-
tions. The vials for pasireotide LAR IM  depot formulation must be stored at refrigerated tem-
peratures between 2°C and 8°C (36°F -46°F) and protected from light until the time of use. The 
pasireotide LAR drug product kit should remain at room temperature for 30- 60 minutes prior to 
preparation of the drug suspen sion. For pasireotide LAR, the reconstitution must be performed 
just prior to administr ation of the suspension. Doses  should be administered immediately after 
preparation. For doses higher than 40 mg, contents of 2 or 3 low dosage vials will be combined 
into one or two injections. Each injection will have maximum volume of 2 ml. A maximum of three vials will be combined per injection and a maximum of 2 injections, at 2 separate injection 
sites of each patient, will be given to reach the dosing level.  
Table 6 Handling and preparation of pasireotide LAR different doses  
Dose (mg)  Volume to  be injected  
20 1 x 20 mg vial +2mL vehicle:  whole volume to be injected  
40 1 x 40 mg vial + 2mL vehicle: whole volume to be injected  
60 1 x 60 mg vial + 2mL vehicle: whole volume to be injected  
 Confidential  Page 24 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
A matching placebo for the pasireotide LAR formulation will be provided by Novartis. Sy ringes 
will be concealed by pharmacy to maintain blinding.  
6.5 Pasireotide LAR dose adjustment  
We will use the oncology dosing (including NETs) as already described above, pasireo tide LAR 
at 60 mg every 28 days being the recommended starting dose for oncological indications If tol-
erability issues occur, the treatment dose may be r educed to pasireotide LAR at 40 mg with next 
scheduled injection. Patients requi ring a dose reduction can return to the higher dose once the 
tolerability issue is resolved. However, patients not able to tolerate the minimum pasireotide 
LAR dose of 20  mg are recommended to be discon tinued from study.  
All dose changes must be recorded on the Dosage Administration Record CRF. Table 7 outlines 
the dose reduction steps for pasireotide.  
Emergency un- blinding will be done at the discretion of the Principal Investigator  
 in cases where she feels it is necessary for the safety of the patient.   
6.5.1  Permitted study drug adjustments  
Toxicity will be  assessed using the NCI -CTC for Adverse Events, version 3.0 (CTCAEv3.0, 
[http://ctep.cancer.gov/forms/CTCAEv3.pdf ]). For patients who are unable to tolerate the prot o-
col-specified SOM230C dosing schedule, dose- adjustment guidelines are given be low. 
6.6 Pasireotide LAR  / placebo dose adjustment  
As already described above, pasireotide LAR /placebo at 60 mg every 28 days is the reco m-
mended starting dose for oncological indications (including NETs). If tolera bility issues occur, 
the treatment dose may be reduced to pasireotide LAR at 40 mg with next scheduled injection. 
Patients requiring a dose reduction can r eturn to the higher dose once the tolerability issue is 
resolved. However, patients not able to tolerate the minimum pasireotide LAR dose of 20  mg 
are recom mended to be discontinued from study.  
All dose changes must be recorded on the Dosage Administration Record CRF. Table 7 ou tlines 
the dose reduction steps for pasireotide.  
Table 7 Guideline for treatment of patients experiencing adverse events 
 
Recommended dose modifications for pasireotide/ placebo  
Worst toxicity  
CTCAE Grade* (value)  Recommended dose modification any time during a cycle of therapy  
No toxicity  Maintain dose level  
Hematologic  
Neutrop enia (ANC)  
Grade 1 (ANC < LLN - 1500/mm3) Maintain dose level  
Grade 2 (ANC < 1500 - 1000/mm3) Maintain dose level  
Grade 3 (ANC < 1000 - 500/mm3) Omit dose until resolved to ≤ Grade 2, then  1 dose level  
• If resolved ≤ 7 days, then maintain dose level  
• If resolved > 7 days, then  1 dose level  
Grade 4 (ANC < 500/mm3) Omit dose until resolved to ≤ Grade 2, then  1 dose level  
• If resolved ≤ 7 days, th en maintain dose level  
• If resolved > 7 days, then  1 dose level  

 Confidential  Page 25 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Thrombocytopenia  
Grade 1 (PLT < LLN - 75,000/mm3) Maintain dose level  
Grade 2 (PLT < 75,000 - 50,000/mm3) Maintain dose level  
Grade 3 (PLT < 50,000 - 25,000/mm3) Omit dose until resolved to ≤ Grade 1, then  1 dose level  
• If resolved ≤ 7 days, then maintain dose level  
• If resolved > 7 days, then  1 dose level  
Grade 4 (PLT < 25,000/mm3) Omit dose until resolved to ≤ Grade 1, then  1 dose level  
Febrile neutropenia (ANC < 1.0 x 109/L, fever  
≥ 38.5°C)  Omit dose until resolved, then  1 dose level  
Renal  
Serum creatinine   
< 2 x ULN  Maintain dose level  
2-3 x ULN  Omit dose until resolved to ≤ Grade 1, then  
• If resolved ≤ 7 days, then maintain dose level  
• If resolved > 7 days, then  1 dose lev el 
Grade 3 (> 3.0 - 6.0 x ULN)  Omit dose and discontinue patient from study treatment  
Grade 4 (> 6.0 x ULN)  Omit dose and discontinue patient from study treatment  
Hepatic  See also section 7.5.4.1   
Bilirubin   
Grade 1 (< 2 x baseline value)  Maintain dos e level  
Grade 2 (2- 3 x baseline value)  Omit dose until resolved to ≤ Grade 1, then  
• If resolved ≤ 7 days, then maintain dose level  
• If resolved > 7 days, then   1 dose level  
Grade 3 (> 3.0 - 10.0 x ULN)  Omit dose until resolved to ≤ Grade 1, then  
• If resolved ≤ 7 days, then maintain dose level  
• If resolved > 7 days, then  1 dose level  
Grade 4 (> 10.0 x ULN)  Omit dose and discontinue patient from study treatment  
NOTE: If grade 3 or 4 hyperbilirubinemia is due to the indirect (unconjugat-
ed) component only, and hemolysis as the etiol ogy has been ruled out as 
per institutional guidelines (e.g. review of peripheral blood smear and ha p-
toglobin determina tion), then  1 dose level and continue treatment at the 
discretion of the i nvestigator  
AST or ALT   
Grade 1 (> ULN - 2.5 x ULN)  Maintain dose level  
Grade 2 (> 2 .5 - 5.0 x ULN)  Maintain dose level  
Grade 3 (> 5.0 and ≤ 8x ULN) For ALT or AST > 5x ULN and ≤ 8x ULN:  
• Study medication should be temporarily interrupted & liver chemistry 
monitored every 3-4days until resolution or return to baseline . 
• If resolution or return to baseline does not occur after 2 weeks, the p a-
tient should be discontinued.  
• If ALT or AST returns to less than 5x ULN, study drug can be r esumed 
and patient can continue study per protocol  
• If ALT or AST rises above 5x ULN anytime after study drug is resumed, 
then study drug should be discontinued immed iately.  
Grade 4 (> 20.0 x ULN)  Omit dose and discontinue patient from study treatment  
Pancreatic  
Pancreatitis   
Grade 1  Maintain dose level  
 Confidential  Page 26 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Grade 2  Maintain dose level  
Grade 3  Omit dose and discontinue patient from study treatment  
Grade 4  Omit dose and discontinue patient from study treatment  
Amylas e and/or lipase   
Grade 1 (> ULN - 1.5 x ULN)  Maintain dose level  
Grade 2 (> 1.5 - 2.0 x ULN)  Maintain dose level  
Grade 3 (> 2.0 - 5.0 x U LN) For asymptomatic:  
Omit dose until resolved to ≤ Grade 1, then  
• If resolved ≤ 7 days, then maintain dose level  
• If resolved > 7 days, then   1 dose level  
For symptomatic:  
Omit dose and discontinue patient from study treatment  
Grade 4 (> 5.0 x ULN)  Omit dose and discontinue patient from study tr eatment  
A CT scan or other imaging study to assess the pancreas, liver and 
gallbladder must be performed within 1 week of the first occurrence of any 
≥ CTCAE grade 3 of amylase and/or lipase.  
Endocrine/metabolic  
Fasting plasma glucose (FPS) or 2 -hour 
postprandial capillary glucose (PPG)   
FPG <126 mg/dL or PPG < 140 mg/dL  Maintain dose level  
Grade 1 (> ULN – 160 mg/dL)  appendix 2 section 12.2.  
Grade 2 (> 160 – 250 mg/dL)  appendix 2 section 12.2.  
Grade 3 (> 250 – 500 mg/dL)  appendix 2 section 12.2.  
Grade 4 (> 500 mg/dL)  appendix 2 section 12.2.  
Cardiac  
Cardiac - prolonged QTc i nterval   
• QTcF > 480 ms and ≤ 500 ms  If at any time a QTcF > 480 ms and ≤ 500 ms is observed a cardiology 
consultation must be sought to re -evaluate the abno rmal ECG finding.  
• QTcF > 500 msec  1. Triplicate ECGs (2 -3 minutes apart) need to be taken ap proximately 1 
hour after the initial ECG.   
2. If the mean QTcF is > 500 ms, the patient must postpone study treat-ment until a cardiologist has re -evaluated the ECG.   
3. The re-evaluation of ECG needs to be done as soon as pract ical but 
within 7 days of the initial abnormal ECG.   
4. If the cardiologist confirms a mean QTcF > 500 ms, the pa tient must 
be discontinued.  
Cardiac general   
Grade 1 or 2  Maintain dose level  
Grade 3  Omit dose until resolved to ≤ Grade 1, then  1 dose level  
Grade 4  Omit dose and discontinue patient from study treatment  
Other adverse events  
Grade 1 or 2  Maintain dose level  
Grade 3  Omit dose until resolved to ≤ Grade 1, then  1 dose level  
Grade 4  Omit dose and discontinue pa tient from study treatment  
Detailed treatment guidance on QT prolongation, hyperglycemia and diarrhea will be provided as appendices of the prot o-
col 
 Confidential  Page 27 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
6.7 Concomitant therapy  
All medications administered within 4 weeks prior to the administration of study drugs and all 
concomitant therapy administered during the study , along with the reasons for therapy , will be 
recorded.  
The investigator should instruct the patient to notify the study site about any new medi cations 
he/she takes after the start of the study drug including all over -the-counter medication. All medi-
cations (other than study drug) and significant non- drug therapies (i ncluding physical therapy 
and blood transfusions) administered after the patient starts treatment with study drug must be listed on t he Concom itant medications/Significant non- drug therapies after start of study drug 
CRF.  
The patients should also be discouraged from taking over -the-counter medic ations for diarrhea. 
The use of prescription medication for diarrhea is also to be avoided while patients are r eceiving 
study drug treatment, but exceptions may be made if the medication is to treat an adverse event.  
The concomitant medication CRF is to be used as an ongoing log, and must be updated as necessary to reflect all medications taken.  
The use of anticoagulant medication should be avoided. Patients currently receiving suppl e-
mental pancreatic enzymes may be enrolled, but they should not start such treatment or i n-
crease the dose while on study.  
The use of concomitant medications that migh t lead to QT prolongation is prohi bited and would 
require the discontinuation of the patient prior to starting the respective QT prolonging medic a-
tion. Please check http://www.azcert.org/medical -pros/drug -lists/browse -drug- list.cfm for a list of 
QT prolong ing drugs.  
6.8 Study drug discontinuation  
Study drug must be discontinued and the subject withdrawn from the trial if the investigator de-termines that continuing would result in significant safety risk for that subject. The following ci r-
cumstances require stud y drug discontinuation:  
Pregnancy  
The occurrence of an adverse event or of a clinically significant laboratory change or abnormal i-
ty that, in the judgment of the investigator, warrants discontinuation of treatment. 
Subjects who have fasting plasma glucose > 240 mg/dL confirmed by repeat measur ement  
Any CTC grade 3 or higher abnormalities in hematology or chemistry parameters judged clini-
cally significant by the Investigator  
Any confirmed QTcF > 500 ms or confirmed increase of QTcF > 60 ms from baseline  
ALT or AST > 3x ULN and Total Bilirubin ≥ 2 x ULN and ALP > 2 x ULN  
ALT or AST > 5x ULN and ≤ 8 x ULN persistent for more than 2 weeks  
ALT or AST > 8 x ULN  
 Confidential  Page 28 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
6.9 Premature patient withdrawal  
Patients may  voluntarily withdraw from the study or be dropped from it at the di scretion of the 
investigator at any time.  These patients will be asked to complete an Early Termination Visit. 
Patients may be withdrawn from the study if any of the fol lowing occur:  
Lack of efficacy  
Uncontrolled diabetes mellitus (DM)  
Pregnancy  
Adver se event(s)  
Abnormal laboratory value(s)  
Abnormal test procedure result(s)  
Protocol violation 
Subject withdrew consent  
Lost to follow -up 
Administrative problems  
Death 
New therapy for disease being investigated  
Disease progression 
6.10 Overall Study Stopping Rul es 
 
Stopping criteria for hyperglycemia and other side effects, e.g. related to changes in hematol o-
gy, chemistry, or cardiac test values are listed in section 6.8 . Pasireotide has already demon-
strated acceptable tolerability and efficacy in several completed or ong oing clinical trials ( page 
38 Investigator Brochure) and the LAR formulation is being examined in a phase 3 study for 
treatment of Acromegaly [STUDY_ID_REMOVED]; Novartis data on file, and for Cushing disease (sc for-
mulation; CSOM230B2305]) recently reported (Colao, Petersenn et al. 2012) . In the latter study 
hyperglycemia- related adverse events occurred in 73% of patients necessitating 6% discontinu-
ing study treatment  Plasma glucose levels increased 10% from baseline compared with a 2% 
increase in placebo (P<0.02) after commencing octreotide treatment and no patient developed 
diabetes in our prior somatostatin analog study us ing OctLAR.  
 
Gastrointestinal problems are the most commonly reported AEs associated with the use of 
SOM230, (predominantly mild diarrhea grade 1 or 2, and nausea requiring no treat ment or study 
discontinuation). In our prior somatostatin analog study in PKD, only 1/42 individuals disconti n-
ued that study after one year (due to steatorrhea) and none discontinued because they devel-
oped diabetes. Based on our prior experience and others’ studies of tolerability and side effects 
associated with OctLAR (and also with lanreotide in PKD and PLD), we do not anticipate there will be pat ient discontinuation >15%, since both drugs have a similar tolerability profile ( Invest i-
gator brochure section 6.2 ). Hence, we do not anticipate we will need to stop this study in this 
patient population due to lack of study power. If there is no efficacy found after the first year 
analysis is complete then we will terminate the open label extension.  We will be monitoring 
each patient closely ( table 8 ) for expected and unexpected drug side effects. If there are any 
 Confidential  Page 29 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
serious suspected adverse reactions (>1) that were unexpected these would be evaluated by 
the spon sor-investigator and the risk/benefit of study continuation would be analyzed.  Novartis 
also r eserves the right to stop the study ( section 13.1.3 ).  
 
• Colao, A., S. Petersenn, et al. (2012). "A 12- Month Phase 3 Study of Pasireotide in 
Cushing's Disease." New England Journal of Medicine 366(10): 914 -924. 
 
 
6.11 End of treatment  
Treatment duration will be completed per the protocol  
7 Visit schedule and assessments   
Table 8 lists all of the  assessments and indicates the visits at which they are to be  performed 
with an “X”. All data obtained from these assessments must be sup ported in the patient’s source 
documentation. In year 2, safety assessments for patient ’s crossing over from placebo to  SOM 
230 will be required. These will be per the same schedule after the first SOM230 injection as 
was performed in year 1 for all patients enrolled.  
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
 Confidential  Page 30 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
 
Table 8 Visit /Study Procedure Schedule 
 
Test / Proc edure  S R Days after 1st injec-
tion Months after initial visit  Mos. 
after 
end 
22/2 29 50 57 85 6 9 1213 15 18 21 24 27 30 33 36 / 
Early 
Term  1 3 
Consent  X                    
History/physical  X       X  X  X  X  X  X   
Height,1 Weight  X       X  X    X  X  X   
ECG2 X X X  X  X X X X X X X X  X  X   
Heme Group3 X       X X X X X X X    X   
PT APTT  X       X  X    X    X   
Metabolic panel4 eGfr5 X  X X X X X X X X X   X    X   
Hemoglobin A1C6 X      X X X X X X X X X X X X  X 
Thyroid ca scade7 X       X  X X X  X  X  X   
MRI (CT)  Scan  X         X        X   
Genoty ping X                    
Cyclosporin le vel8 X    X   X X X X X  X    X   
Microalb umin X         X    X    X   
Fasting gl ucose9 X X X  X  X X X X X X X X  X  X X  
Pregnancy Test10 X         X           
QOL SF -36v2T M X       X  X  X  X  X  X   
SOM230/Placebo11  X  X  X X X X X X X X X X X X X   
Concomitant meds  X → X X X X X X X X X X X X X X X X   
Gallstone (6 mo)12        X    X  X  X     
PK Bloods  X   X   X X  X           
  
 S= Screening  R = Randomization 
 1 Height required only at pre- study  
2 12 lead ECG  & interpretation at screening and ½ hour after first injection. Repeat ECG on 21st day 
after injection for the first 3 months then every third month. All ECGs are faxed to the Mayo Clinic ECG 
Core lab.  
3 Includes WBC with differential  
4 Comprehensive fasting metabolic panel includes: albumin, total bilirubin, calcium, CO 2, (bicarbonate) 
chloride, creatinine, BUN, potassium, total protein, sodium, AST, ALT, ALP,, and glucose. Liver func-
tion tests are assessed at baseline (if baseline LFTs are done within 7 days of day 1 of treatment 
they do not have to be repeated on day 1), day 22 after first injection, day 29, day 50, 57 and 85. After 
day 85 and the 4th LAR Injection, monitoring should follow the existing protocol schedule. Day 22 & 50 
LFTs must be available & assessed prior to dosing on days 29 (2nd injection) and 57 (3rd injection).  
5 Only in patients with ass ociated PKD.  
6 Hemoglobin A1C is done at baseline and 3 monthly 
7 Thyroid function is also acceptable if checked within 30 days of the screening visit  
8 Bi-weekly cyclosporin levels will be monitored for the first month in enrolled patients who are on this 
medication (mail in test )  
9 Plasma glucose is required 6 hours after first injection. Monitor FPG or finger stick at baseline and at 21
st day of treatment for first 3 months. Monitor FPG or finger stick monthly (or as clinically appropr i-
ate), thereaf ter. 
 Confidential  Page 31 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
10 Women of childbearing potential only (urine pregnancy test) . If CT scan is needed, a negative pr eg-
nancy result will need to be obtained prior to performing the CT. For women of child bearing potential 
who will be having an MRI – a pregnancy test  is not required at month 12.  
11 SOM230/placebo IM injections will be given every 28 days, +/- 2 days.  
12 No gallstone assessment is needed on visits where MRI is performed, as gallstones will be detected 
on MRI if pr esent.  
13 In year 2, safety assessments for patients crossing over from placebo to SOM 230 will be 
required. These will be per the same schedule after the first SOM230 injection as was 
performed in year 1 for all patients enrolled.  
 
At a minimum the following safety evaluations (Table 9)  are to be included in all prot ocols. 
Table 9 Core safety evaluation and frequency  
 
Evaluation  Frequency  
 
ECG  Baseline ECG prior to and 30 minutes after the first dose.  
Repeat ECG on 21st day after injection for the first 3 months  
Repeat ECG every 3 months thereafter.  
Gallstone asses sment 
by CT/MRI is  part of the 
evalu ation Baseline and every 6 months (done by ultrasound, at Mayo outside of 
baseline 12 and 36 months visits when MRI is performed)  
Fasting glucose fi nger 
stick Monitor FPG or finger stick at baseline and at 21st day of treatment for the first 
3 months.  
Monitor FPG or finger stick monthly (or as clinically appropriate), thereafter.  
Monitor of FPG 4 weeks after the end of the treatment is recommended.  
TSH/Free T4  Baseline and at 6 months  
HbA1c*  Baseline and every 3 months  
Monitoring HbA 1c 3 months after the end of the treatment is reco mmended  
7.1 Inform ation to be collected on screening failures 
Information on all screen failures will be collected and the analysis will be performed for all pa-
tients will be included who received at least one dose of the ran domized study drug.  
7.2 Patient demographics/other baseline characteristics  
The ADPKD database at the Mayo Clinic includes 4577 patients. Approximately 500 patients with ADPKD or ADPLD are seen in the PKD Clinic, the Renal Transplant and Hepatobiliary Cli n-
ics every year. Mayo Clinic has the largest experience in combined hepatic resection/cyst fene s-
tration for severe PLD. Ten percent of the patients undergoing renal transplantation at the Mayo 
Clinic in Rochester (~250 patients per year) have ADPKD. Pregnant women, children, prison-
ers, institutionalized individuals will not be randomized to this study. The proposed consent form 
is attached to this proposal.
 
 Confidential  Page 32 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
7.3 Treatments  
All current medication used to treat diabetes mellitus should be documented 
All medications, including over -the-counter medication, taken prior  to study drug administration 
and which continue during the course of the study must be doc umented  
Compliance will be assessed by the investigator and/or study personnel at each visit. Records 
of study medication used, treatment administered, and intervals between visits will be kept du r-
ing the study. Drug accountability will be noted. Patients will be asked to return all used medic a-
tion ampoules at each visit and the end of the study.  
7.4 Efficacy  
7.4.1  Liver & total kidney volume, hepatic cyst volume, renal cyst v olume 
7.4.1.1  Primary outcome 
The primary outcome is the percent change in liver volume as assessed by MR at baseline, 12 and 36 months follow -up. Patients will also be classified as “responders” if their liver volume de-
creases, does not change, or increases by <2 % over the 12 month study period. The MR tec h-
niques for imaging and interpretation of volumetric measurements established in the CRISP study will be em ployed in the present study, as early results from the CRISP study indicate that 
this MR protocol will pr ovide an effective means for longitudinal evaluation of liver and kidney 
volume and of cyst volume and is much more sensitive in detecting cholelithiasis when com-
pared to CT, because CT cannot differentiate be tween the density of bile in the gallbladder and 
the more common, non -calcified gallstones. T- 2 weighted images on MR can easily demon-
strate stark contrast between the bright fluid (bile) in the gallbladder from the dark gallstones which do not have any signal intensity on MRI. The MR Procedure comprises of the follow ing 
(30 minutes):  
1. Since no gadolinium will be used in this study, patients will not have an angiocatheter 
placed at the time of their MRI. (See exception for patients undergoing CT be low.)  
2. ECG pads will be placed over the chest. If ECG gating is not available or functioning, it may be replaced with a peripheral pulse gating. Hair may need to be shaved off to place the 
leads.  
3. Subjects will be placed supine on the MR table with their arms to their sides.  
4. A phased- array surface coil  will be positioned with its center over the liver.   
5. Scout scan to locate the scan range of the entire liver.  
6. The field -of-view (FOV) should be kept as small as possible (30 -35 cm) wit hout producing 
wrap -around artifacts.  
7. Obtain breath -hold coronal Regular T2 scan (SSFSE/HASTE with fat sat) with 9mm fixed 
slice thickness, usually achievable in a single breath- hold.  
8. Obtain breath -hold coronal Regular T2 scan (SSFSE/HASTE with fat sat) of the liver with 
adjusted slice thickness, 3- 9 mm, i.e. the  slice thickness best attainable with a single 
breath -hold (the adjusted slice thickness may not r emain the same in a follow -up MR scan if 
there is a change in the sub ject's breath- hold capacity or liver size).  
9. Repeat the scan over the kidneys with the same slice thickness.  
The measurements of liver, kidney and cyst volumes will be performed without knowledge of group assignment using the technology developed for the CRISP study.
36 Liver and kidney vol-
 Confidential  Page 33 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
umes will be measured in T1- weighted i mages with a stereology method and calculated from 
the set of contiguous images by summing the products of the area measurements and slice 
thickness. A region- based threshol d method will be used to cal culate cyst volumes.  
In patients who are unable to undergo MRI ( e.g. due to claustrophobia) a CT scan of the liver 
and kidneys will be substituted. CT scans will be performed with or without contrast, de pending 
of renal function. If estimated GFR is greater that 60 iodinated IV contrast will be employed. If 
renal func tion is less than 60mls/min, no iodinated contrast will be used. A peripheral IV cannula 
will be inserted for patients requiring IV contrast and removed immediately  after the scan is 
completed.  
7.4.1.2  Secondary efficacy assessments  
Absolute and percent changes in liver volume in the placebo group before (year 1) and after 
(years 2- 3) cross -over to active treatment will be assessed base on comparison of baseline vol-
umes as assessed by MRI/CT in each subject. The measurements will be performed in the Bio-
medical imaging core facility by blinded assessors. Similarly, absolute and percent changes in 
liver volume will be assessed in the treatment arm during years 2 -3 compared to the placebo 
arm during year 1. Similarly, c hanges in kidney volume from baseline at 12 and 36 months in 
individuals with ADPKD will be assessed by MRI.  
Changes in eGFR, vital signs, creatinine, liver function tests, APTT, PT, glucose values  from 
baseline (or from month 3) at 12 and 36 months in all ind ividuals and treated as a continuous 
variable. Data from ADPLD patients will be excluded from the renal outcome sub -analyses.  
Measurement of Effect (Subjective Response): 
Changes in quality of life at baseline and 12 and 36 months  will be measured by SF36-
questionnaire QOL -questionnaire ( SF-36v2™).  
7.4.1.3  Tertiary objectives  
We will assess l ongitudinal changes beyond 12 months in the above factors, stratified by trea t-
ment sequence.  
7.4.2  Treatment/Follow -up Decisions at Patient Evaluations  
Response to treatment will be analyzed by measuring changes in liver volume. The study is i n-
tended to provide information after 12 months of treatment. Follow-up decisions will proceed as 
follows: if the treatment is found to be definitively or possibly effective (reduction in liver vol ume, 
no increase or increase < 2% per year), all participants treated with will be offered Pasi reotide 
LAR® Depot treatment for another 24 months. The partic ipants treated with placebo will also be 
offered at this point treatment with Pasireotide LAR® Depot for 24 months.   
7.5 Safety  
Safety assessments will consist of monitoring and recording all adverse events, including ser i-
ous adverse events, the regular monitoring of hematology (includ ing glycosylated hemog lobin 
and coagulation parameters), blood chemistry (i ncluding fasting glucose, thyroid function tests), 
urine for microalbumin, regular monitoring of vital signs, gallbladder by MRI/CT  ultrasound, will 
be recorded from study enrollment until study completi on. 
Patients with diabetes are to be instructed to check blood glucose levels via a fingerstick sev eral 
times daily, particularly for the first few days of treatment.  
 Confidential  Page 34 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
7.5.1  Adverse events  
An adverse event for the purposes of this protocol is the appearance of (or worsening of any 
pre-existing) undesirable sign(s), symptom(s), or medical condi tion(s) occurring after signing the 
informed consent even if the event is not co nsidered to be related to the study drug(s). Please 
refer to the adverse event section of the protocol  for the protocol -specific definitions of study 
drug and study trea tment.  
Adverse events will be assessed according to the Common Toxicity Criteria for Adverse Events [CTCAE] version 3.0. If CTCAE grading does not exist for an ad verse event, the severity of mild, 
moderate, severe, and life- threatening, or grades 1 - 4, will be used. CTCAE grade 5 (death) will 
not be used in this study; rather, this information will be collected in the End of Treatment. A d-
verse event monito ring should be continued for at least 4 weeks following the last dose of study 
treatment.  
Adverse events (but not serious adverse events) occurring before starting study treatment but after signing the informed consent form are recorded on the Medical History/Current Medical 
Conditi ons Electronic Case Report Form. A bnormal laboratory values or test results constitute 
adverse events only if they induce clinical signs or symptoms, are considered clinically signifi -
cant or r equire therapy (e.g., any hematologic abnormality that requires  transfusion or cytokine 
treatment); and should be recorded on the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them. In addition, isolated abnormal laboratory values that are con-sidered clinically significant (e.g., cause study discontinuation or constitutes in and of itself a S e-
rious Adverse Event) should be recorded on the Adverse Events CRF. SAEs occurring after signing the I nformed Consent are recorded on the Adverse Event CRF.  
The occurrence of adverse events should be sought by non- directive questio ning of the patient 
at each visit during the study. Adverse events also may be detected when they are volun teered 
by the patient during or between visits or through physical examination, laboratory test, or other 
assessments. As  far as possible, each adverse event should be evaluated to dete rmine:  
1. The severity grade (CTCAE grade 1 -4) 
2. Its relationship to each study drug (suspected/not suspected)  
3. Its duration (start and end dates or if continuing at final exam)  
4. Action taken (no action taken; study drug dosage adjusted/temporarily interrupted; study 
drug permanently discontinued due to this adverse event; concomitant medication t aken; 
non-drug therapy given; hospitalization/prolonged hospi talization)  
5. Whether it is serious, where a se rious adverse event (SAE) is defined as one which:  
• Is fatal or life -threatening 
• Results in persistent or significant disability/incapacity  
• Constitutes a congenital anomaly/birth defect  
• Requires inpatient hospitalization or prolongation of existing hospitalization, unless hos-
pitalization is for: 
• Routine treatment or monitoring of the studied indication, not associated with any de-
terioration in con dition (specify what this includes)  
• Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since sig ning the informed consent  
• Treatment on an emergency outpatient basis for an event not fulfilling any of the de f-
initions of a SAE given above and not resulting in hospi tal admission  
 Confidential  Page 35 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
• Social reasons and respite care in the absence of any deterioration in the patient’s 
general condition  
• Is medically significant, i.e., defined as an event that jeopardizes the patient or may r e-
quire medical or surgical intervention to prevent one of the outcomes listed above 
Unlike routine safety assessments, SAEs are monitored continuously and have special reporting requirements; see protocol section on Serious Adverse Event reporting.  
All adverse events should be treated appropriately. Such treatment may include changes in study drug treatment including possible interruption or discontinuation, starting or stopping con-
comitant treatments, changes in the frequency or na ture of assessments, hospitalization, or any 
other medically required inter vention. Once an adverse event is detected, it should be followed 
until its resolution, an assessment should be made at each visit (or more frequently, if nece s-
sary) of any changes in its severity, its suspected relationship to the study drug(s), any of the 
interventions required to treat it, and its ou tcome.  
Information about common side effects already known about the investigational drug can be found in the [Investigator’s Brochure]  or will be communicated be tween IB updates in the form of 
Investigator Notifications. This inform ation will be included in the patient informed consent and 
should be discussed with the patient during the study as needed. 
7.5.2  Vital signs  
Body weight, body temperature, supine blood pressure, and supine pulse rate will be assessed. 
Height will be noted du ring the screening/baseline period.  
7.5.3  Performance status  
SF36 quality of life form  and Gastrointestinal Symptom Questionnaire will be used.  
7.5.4  Laboratory evaluations 
Patients are to fast overnight for 8 hours prior to all biochemistry samples being taken. Blood samples are to be taken in the morning. Water is allowed during this time. Laboratory samples 
will be analyzed locally at Mayo Clinic. Albumin, alk aline phosphatase, total bilirubin, calcium, 
chloride, creatinine with calc ulated eGFR, γ -GT, fasting blood glucose, potassium, total protein, 
AST, ALT , sodium, urea/BUN. If the total bilirubin concentration is increased above 1.5 times 
the up per normal limit (UNL), total bilirubin should be differentiated into the direct and indi rect 
reacting bilirubin.  
7.5.4.1  Abnormal liver function management:  
Perform within 72 hours of awareness of abnormal LFTs:  
Perform liver -directed medical history and physical examination (i.e. assess occupational haz-
ards, concomitant medications including OTC meds, intercurrent illness, etc)  
Liver chemistry tests: ALT, AST, total bilirubin, (fractionate to direct/indirect bilirubin if total bil i-
rubin is > 2.0x ULN), Alb, PT (INR), ALP, and GGT 
Perform hepatitis screen: anti- HAV, IgM (to confirm acute hepatitis A) , HbsAg, Anti -HBc, anti -
HCV (if positive PCR v iral load should be assessed), Anti -HEV, ANA antibodies, anti -smooth 
muscle anti -bodies, CMV, EBV  
Perform abdominal ultrasound (liver and biliary tree) 
 Confidential  Page 36 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Liver chemistry tests should be monitored every 3- 4 days f or LAR studies until resolution or r e-
turn to baseline status.   
For ALT or AST > 5x ULN and ≤ 8x ULN:  
o Study medication should be temporarily interrupted and liver chemistry tests 
monitored every 3- 4 days until resolution or return to baseline  
o If resolution or return to baseline does not occur after 2 weeks, the patient should 
be discontinued.  
o If ALT or AST returns to less than 5x ULN, study drug can be resumed and pa-
tient can continue study per protocol  
o If ALT or AST rises above 5x ULN anytime after study drug is resumed, then study drug should be discontinued immediately.  
Resolution return to baseline does not occur after two weeks the patient should be disconti nued 
If ALT or AST rises about 5X ULN anytime after study drugs resumed and study drug to be dis-continued immediately  
Study medication should be discontinued immediately if any of the discontinuation criteria be low 
are met:  (see appendix 4)  
ALT or AST > 3x ULN and Total Bilirubin > 2x ULN and ALP < 2x ULN  
ALT or AST > 5x ULN and ≤  8x ULN persistent for more than 2 weeks  
ALT or AST > 8x ULN  
Re-challenge of study medication is prohibited once discontinuation crit eria are met.  
7.5.4.2  Thyroid function tests  
Free T4 and TSH will be assessed prior  to enrollment and at 6 months.  
7.5.4.3  Urine tests:  
Serial spot urine microalbumin measurements will be followed.  
7.5.4.4  Hormone assessments  
GH, IGF -1 and prolactin (PRL),  will not be assessed.   
7.5.4.5  Urinalysis 
Specific gravity, pH, glucose, protein, bilirubin, ketones, leukocytes and blood will be assessed. 
7.5.4.6  Pregnancy test  
Study drug treatment should be withdrawn in the event of pregnancy. To e nsure patient safety 
each pregnancy  must also be reported to Novartis within 24 hours of learning of its occurrence. 
The pregnancy should be followed up to determine outcome, including spontaneous or volun-
tary termination, details of birth, and the presence or absence of any birth defects, congenital 
abnormalities or maternal and newborn complications. Any SAE experienced during pregnancy 
must be reported on the SAE Report Form.  
 Confidential  Page 37 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
7.5.4.7  Gallbladder Imaging  
The gallbladder will be imaged at baseline (by MRI or CT) and repeated 6 monthly until the end 
of study. Patients with a history of symptomatic cholelithiasis are excluded from par ticipating in 
the study.  
7.5.4.8  Electrocardiogram (ECG)  
A 12-lead electrocardiogram (ECG) and rhythm strip will be performed at bas eline and 30 min-
utes after the first dose o ne half and 3 monthly for the first year  and every 6 months in year 2. 
Repeat ECG on the 21st day after the injection, then  every 3 months thereafter.  
If a clinically significant abnormality is detected, the electrocardiogram will be r epeated at the 
discr etion of the Investigator until the abnormality has been r esolved. A cardiology consultation 
must be sought as soon as practical but within 7 days of the initial abnormal ECG and the cardi-
ologist must re- evaluate the ECG (this can be done by the central cardiologist). An echocardi o-
gram may also be r equired.  
• If a QTcF > 480msec is NOT confirmed, no further action needs to be taken.  
• If a QTcF > 480msec is confirmed, a cardiologist must perform a thorough examination 
(such as reviewing baseline ECG, concurrent  medications and performing a cardiovas-
cular examination, including at least a cardiac auscultation) to assess the patient for car-
diovascular risk fa ctors.  
7.6 Pharmacokinetics  
Blood levels of pasireotide will be done in this protocol.  
8 Other Safety Considerations:  
The potential risks to patients should be limited to study drug use as no specific change in diet and pharmacologic treatment will be introduced throughout the study, unless deemed clinically 
appropriate to control blood pressure or limit the signs  of renal or liver dysfunction. Antihyper-
tensive treatment will be adjusted in order to maintain a target systolic/diastolic blood pressure <130/80 mm Hg. Blood glucose levels will be carefully monitored during the study and antidi a-
betic therapy adjusted if indicated. Other medications necessary for medical management or symptomatic treatment, including analgesics, anti emetics, antidiarrheals, and thyroxine, will be 
administered as clinically indi cated. Claustrophobic patients will be provided a standing order of 
oral lorazepam 1mg 45 minutes before their MRI according to the standard Mayo Radiology Department Pr otocol.  
The NCI common toxicity criteria 3.0 will be used to classify adverse events (both patient and event counts) by organ system (neuro, GI, etc.), individually, by sever ity and, for each severity, 
by investigator -assessed relationship to study drug. Fisher’s exact test will be used to compare 
treatment groups (placebo, SOM230) regarding adverse events during year 1. Patients who r e-
ceived at least one dose of the randomized study drug will be included. Adverse events in years 
2 and 3 (all subjects on SOM230) will be reported separately. A data safety committee will meet every six months  (comprising of two physicians; ). The 
committee will meet with the study coordinator and PI and review safety labs and monitoring and study conduct.  
 

 Confidential  Page 38 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
 
 
8.1.1.1 Adverse events  
Information about all adverse events, whether volunteered by the subject, discovered by inves-
tigator questioning, or detected through physical examination, labo ratory test or other means, 
will be collected and recorded and followed as appr opriate.  
An adverse event is the appearance or worsening of any undesirable sign, sym ptom, or medical 
condition occurring  after starting the study drug even if the event is not considered to be related 
to study drug. Medical conditions  / diseases present before starting the study drug are only con-
sidered AEs if they worsen after starting the study drug. Abnormal laboratory values or test r e-
sults constitute ad verse events only if they induce clinical signs or symptoms, are considered 
clinically significant, or require therapy.  
The occurrence of adverse events should be sought by non- directive questio ning of the patient 
at each  visit during the study. Adverse events also may be de tected when they are volunteered 
by the patient during or b etween visits or through physical examination, laboratory test, or other 
assessments. As far as possible, each adverse event should be evaluated to determine:  
• the severity grade (mild, moderate, severe) or (grade 1- 4) 
• its relationship to the study drug(s) (suspected/not suspected)  
• its duration (start and end dates or if continuing at final exam)  
• action taken (no action taken; study drug dosage adjusted/temporarily i nterrupted; study 
drug permanently discontinued due to this adverse event; concomitant medication taken; 
non-drug therapy given; hospitalization/prolonged hospi talization)  
• whether it constitutes a serious adverse event (SAE)  
All adverse events should be treated appropriately. Such treatment may include changes in 
study drug treatment including possible interruption or discontinuation, starting or stopping con-comitant treatments, changes in the frequency or na ture of assessments, hospitalization, or any 
other medically required inter vention. Once an adverse event is detected, it should be followed 
until its resolution, and assessment should be made at each visit (or more frequently, if nece s-
sary) of any changes in severity, the suspected relationship to the study drug, the interven tions 
required to treat it, and the outcome.  
Information about common side effects already known about the investigational drug can be 
found in the [Investigators’ Brochure]  or will be communicated be tween IB updates in the form of 
Investigator Notifications. This infor mation will be included in the patient informed consent and 
should be discussed with the patient during the study as needed.  
8.1.1.1  Serious adverse events 
Information about all serious adverse events will be collected and recorded. To ensure patient safety each serious adverse event must also be reported to Novar tis within 24 hours of learning 
of its occurrence. A serious adverse event is an undesirable sign, symptom or medical condition which:  
• is fatal or l ife-threatening 
• results in persistent or significant disability/incapacity  
 Confidential  Page 39 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospitalization or prolongation of existing hospitalization, unless hospi-
talization is for:  
o routine treatment or monitoring of the studied indication, not associated with any de-
terioration in condi tion (specify what this includes)  
o elective or pre -planned treatment for a pre- existing condition that is unrelated to the 
indication under study and has not worsened since the  start of study drug  
o treatment on an emergency outpatient basis for an event not fulfilling any of the def i-
nitions of a SAE given above and not resulting in hospi tal admission  
o social reasons and respite care in the absence of any deterioration in the patient’s 
general condition  
• is medically significant, i.e., defined as an event that jeopardizes the patient or may r e-
quire medical or surgical intervention to prevent one of the outcomes listed above 
8.1.2  Novartis instructions for rapid notification of serious adverse events  
The principal investigator has the obligation to report all serious adverse events to the FDA, IRB, and Novartis Pharmaceuticals Integrated Medical Safety (IMS).  
All events reported to the FDA by the investigator are to be filed utilizing the Form FDA 3500A (MedWatch Form).  
All events must be reported, by FAX ), to Novartis Pharmaceuticals IMS De-
partment within 24 hours of learning of it s occurrence. This includes serious, related, labeled 
(expected) and serious, related, unlabeled (un expected) adverse experiences. All deaths during 
treatment or within 30 days following completion of active protocol therapy must be reported within 1 wor king day.  
Any serious adverse event occurring after the patient has provided informed con sent and  until 4 
weeks after the patient has stopped study participation must be reported. This includes the per i-
od in which the study protocol inte rferes with the standard medical treatment given to a patient 
(e.g. treatment withdrawal during washout period, chan ge in treatment to a fixed dose of con-
comitant medication).  
Serious adverse events occurring more than 4 weeks after study discontinua tion need only be 
reported if a relationship to the Novartis study drug (or therapy) is suspected.  
For Comparator Drugs/Secondary Suspects (Concomitant Medications), all serious adverse ex-
periences will be forwarded to the product manufacturer by the i nvestigator.  
8.1.2.1  Pregnancies  
Any pregnancy that occurs during study participation should be reported. To ensure patient 
safety each pregnancy must also be reported to Novartis within 24 hours of learning of its occur-
rence. The pregnancy should be followed up to de termine outcome, including spontaneous or 
voluntary termination, details of birth, and the presence or absence of any bir th defects, conge n-
ital abnormalities or m aternal and newborn complications.  

 Confidential  Page 40 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
9 Protocol amendments, or changes in study conduct  
Any change or addition (excluding administrative) to this protocol requires a written protocol 
amendment that must be reviewed by Novartis and the investigator before implementation. Amendments significantly affecting the safety of subjects, the scope of the investigation or the 
scientific quality of the study require additional approval by the IRB at each study center.  A 
copy of the written approval of the IRB must be provided to Novartis. Examples of amendments 
requiring such approval are:  
1. increases in drug dose or duration of exposure of subjects,  
2. significant changes in the study design (e.g. addition or deletion of a con trol group),  
3. increases in the number of invasive procedures, 
4. addition or deletions of a test procedure required for monitoring of safety.  
These requirements for approval should in no way prevent any immediate action from being taken by the investigator or by Novartis in the interests of preserving the safety of all patients i n-
cluded in the trial. If an immediate change to the protocol is felt to be necessary by the invest i-
gator and is implemented for safety reasons Novartis must be notified and the IRB at the center must be informed imm ediately. Amendments affecting only administrative aspects of the study 
do not require formal protocol amendments or IRB approval but the IRB must be kept i nformed 
of such administrative changes. Examples of administrative changes not r equiring formal prot o-
col amendments and IRB approval include:  
1. changes in t he staff used to monitor trials,  
2. minor changes in the packaging or labeling of study drug.  
10 Data management  
10.1 Data collection  
Every patient will have a study folder containing source documents, report forms; original signed 
consent, and stored in a locked area in the study coordinator’s office  
 Serial data entry recording the information required by the protocol from ini-
tial and subsequent visits will be entered on SDMS spreadsheets, and maintained on a pas s-
word protected Nephrology secure server. Statist ical methods  
10.2 Statistical methods  
Demographics and laboratory data will be plotted (e.g. box plots) and summ arized by treatment 
group. Frequency distributions will be used to describe cat egorical values and basic summary 
statistics (mean, standard deviation, median, and inter- quartile range) used to describe continu-
ous values. All tests will be two- sided with alpha level 0.05. For quantitative endpoints (e.g. 
change in kidney and liver volumes, renal function, and SF- 36 scales) the two- group independ-
ent samples t -test will be used to test for an effect of treatment. Should the assumptions of nor-
mality and equality of variances be untenable, we will consider a data trans formation or use of 
the Wilcoxon rank sum test. Both point estimates (mean) and 95% confidence intervals will be 
used to summarize treatment effects. For qualitative endpoints (e.g. presence or absence of r e-
sponse) we will compare treatment groups using the chi -square or Fisher’s exact test as appr o-
priate.  
Efficacy (Liver & kidney): The primary analysis of treatment eff icacy will follow intent -to-treat 
principles, attempting to include all randomized patients. For the primary endpoint (change in 

 Confidential  Page 41 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
liver volume) we will not be able to include any one without a 12 month MRI  (kidney volumes will 
be handled in the same way) . For the “response” endpoints, those without a 12 month MRI will 
be included in the analysis as non -responders. Se condary analysis – Efficacy (QOL): We will 
have up to 5 longitudinal assessments of QOL for each patient. Repeated measures analysis of 
variance will be used to compare mean QOL profiles over time between treatment groups. Al so, 
within patient rates of change  or slopes in QOL measures will be estimated (using simple linear 
regression) and compared between groups using the two- sample t -test.  
Secondary analysis– Kidney volume will be measured as part of the efficacy analysis: 
AEs (both patient and event counts) will be tabulated by organ system (neuro, GI, etc.), indivi d-
ually, by severity and, for each severity, by investigator -assessed relationship to study drug. 
Fisher’s exact test will be used to compare treatment groups regarding adverse events. P atients 
who received at least one dose of the randomized study drug will be included.  
Statistical power: The primary endpoint is one year percentage change in liver volume. Prior 
data in un treated patients suggest a growth rate (SD) of 5(±3) % per year4,37. We have planned 
a 2:1 randomization in order to allow as many patients as possible to receive SOM230. The goal 
is to de tect up to a 7.3% percentage point decrease in the mean cyst growth using SOM230 
LAR® Depot. With 15 placebo and 30  SOM230 patients, the study will have 80% power (al-
pha=.05, two- sided) to detect a 7 percentage point difference. To allow for dropouts (1 pl acebo 
and 2 SOM230 patients without endpoint data); the study will randomize 16 placebo and 32 SOM230 patients. For any quantitative endpoint the study is powered to detect a diffe rence in 
treatment means of at least one standard deviation. Secondary endpoints include com parison of 
responder rates (based on liver and renal growth) and adverse event rates between the two 
groups. With 16 and 32 patients, a true placebo response (or ad verse event rate) of 8 % (1 of 
13) vs. 30, 40, or 50% for SOM230 can be detected with 45%, 70%, and 88% power, respec-
tively.  
11 References  
1. Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT. Epidemiology of adult 
polycystic kidney disease, Olmsted County, Minnesota: 1935- 1980. Am J Kidney Dis  
1983;2:630 -639. 
2. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009;60:321- 337. 
3. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet  
2007;369:1287 -1301.  
4. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ , Guay -Woodford LM, Baumgarten 
DA, King BF, Jr., Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal -dominant polycystic kidney disease: the Consortium for Radiologic Imaging 
Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol  2006;1:64- 69. 
5. Li A, Davila S, Furu L, Qian Q, Tian X, Kamath PS, King BF, Torres VE, Somlo S. Mutations 
in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet  
2003;72:691 -703. 
6. Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, Cai Y, Kamath PS, King BF, 
Azurmendi PJ, Tahvanainen P, Kaariainen H, Hockerstedt K, Devuyst O, Pirson Y, Martin RS, Lifton RP, Tahvanainen E, Torres VE, Somlo S. Mutations in SEC63 cause autosomal dominant 
polycystic liver disease. Nat Genet  2004.  
 Confidential  Page 42 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
7. Li JP, Lee KY, Chang TM, Chey WY. MEK inhibits secretin release and pancreatic secretion: 
roles of secretin- releasing peptide and somatos tatin. Am J Physiol Gastrointest Liver Physiol  
2001;280:G890- 896. 
8. Gong AY, Tietz PS, Muff MA, Splinter PL, Huebert RC, Strowski MZ, Chen XM, LaRusso NF. 
Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via 
SSTR2 on cholangiocytes. Am J Physiol Cell Physiol 2003;284:C1205- 1214.  
9. Tietz PS, Holman RT, Miller LJ, LaRusso NF. Isolation and characterization of rat 
cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry  1995;34:15436- 15443.  
10. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C. 
Signal transduction of somatostatin receptors negatively controlling cell proliferation. Journal of 
physiology, Paris  2000;94:205- 210. 
11. Forrest JN, Jr. , Reichlin S, Goodman DB. Somatostatin: an endogenous peptide in the toad 
urinary bladder inhibits vasopressin- stimulated water flow. Proc Natl Acad Sci U S A  
1980;77:4984 -4987.  
12. Friedlander G, Amiel C. Somatostatin and alpha 2- adrenergic agonists selec tively inhibit 
vasopressin- induced cyclic AMP accumulation in MDCK cells. FEBS Lett 1986;198:38 -42. 
13. Winkler SN, Torikai S, Levine BS, Kurokawa K. Effect of somatostatin on vasopressin-
induced antidiuresis and renal cyclic AMP of rats. Mineral and elect rolyte metabolism  1982;7:8-
14. 
14. Mountokalakis T, Levy M. Effect of somatostatin on renal water handling in the dog. 
Canadian journal of physiology and pharmacology  1982;60:655- 664. 
15. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic 
cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 
3',5'- cyclic monophosphate. Gastroenterology  2007;132:1104 -1116.  
16. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene -Iordache B, Remu zzi G, 
Epstein FH. Safety and efficacy of long- acting somatostatin treatment in autosomal -dominant 
polycystic kidney disease. Kidney International  2005;68:206 -216. 
17. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, 
de Man RA, Drenth JP. Lanreotide reduces the volume of polycystic liver: a randomized, double- blind, placebo- controlled trial. Gastroenterology  2009;137:1661- 1668 e1661- 1662.  
18. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, 
Holmes DR, Rossetti S, Harris PC, LaRusso NF, Torres VE. Randomized Clinical Trial of Long-
Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. Journal of 
the American Society of Nephrology  2010;21:1052- 1061.  
19. Caroli A, A ntiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P. Reducing 
polycystic liver volume in ADPKD: effects of somatostatin analog  octreotide. Clin J Am Soc 
Nephrol  2010.;5:783 -789. 
20. Hogan M, Masyuk T, Page LJ, Holmes D, Li X, Bergstralh EJ, Rossetti S, Kim B, Glockner 
J, Harris P, LaRusso N, VE T. Somatostatin Analog Therapy for Severe Polycystic Liver Disease: Results after Two Years American Society of Nephrology. Denver, CO, 2010.  
 Confidential  Page 43 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
21. Hogan MC, Masyuk; TV, Page L, III DRH, Li X, Bergstralh EJ, Mira MVI, Kim B, King BF, 
Glockner J, LaRusso NF, Torres VE. Somatostatin Analog Therapy for Severe Polycystic Liver 
Disease: Results After Two Years. Submitted  2011.  
22. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human 
recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology  2004;80 Suppl 1:47- 50. 
23. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013 -
3018.  
24. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering 
EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol  2004;15:966 -973. 
25. ONO K, SUZUKI T, MIKI Y, TANIYAMA Y, NAKAMURA Y, NODA Y, WATANABE M, 
SASANO H. Somatostatin Receptor Subtypes in Human Non- functioning Neuroendocrine 
Tumors and Effects of Somatostatin Analog SOM230 on Cell Proliferation in Cell Line NCI -
H727. Anticancer Res earch  2007;27:2231 -2239.  
26. van Keimpema L, de Man RA, Drenth JP. Somatostatin analogs  reduce liver volume in 
polycystic liver disease. Gut 2008;57:1338- 1339.  
27. van Keimpema L, Drenth JP. Effect of octreotide on polycystic liver volume. Liver Int  2009.  
28. Peces R, Cuesta -Lopez E, Peces C, Perez -Duenas V, Vega- Cabrera C, Selgas R. 
Octreotide reduces hepatic, renal and breast cystic volume in autosomal -dominant polycystic 
kidney disease. International urology and nephrology  2010.  
29. Boehm S, Betz H. Somatostatin inhibits excitatory transmission at rat hippocampal 
synapses via presynaptic receptors. Journal of Neuroscience 1997;17:4066- 4075.  
30. Koenig JA, Edwardson JM, Humphrey PPA. Somatostatin receptors in Neuro2A 
neuroblastoma cells: ligand internalization. British Journal of Pharmacology  1997;120:52- 59. 
31. Bloch B, Dumartin B, Bernard V. In vivo regulation of intraneuronal trafficking of G protein-
coupled receptors for neurotransmitters. Trends in Pharmacological Sciences  1999;20:315 -319. 
32. Masyuk T . Polycystic kidney and liver disease; role of Octreotide and Pasireotide in hepato-
renal cystogenesis. . Rochester: Mayo Clinic, 2011.  
33. Schmid HA. Pasireotide (SOM230): Development, mechanism of action and potential 
applications. Molecular and Cellular  Endocrinology  2008;286:69- 74. 
34. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid- Smith P, Danks DM. Evaluation of 
ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet  
1994;343:824 -827. 
35. Reynolds DM, Falk CT, Li A, King BF, Kamath PS, Huston J, 3rd, Shub C, Iglesias DM, 
Martin RS, Pirson Y, Torres VE, Somlo S. Identification of a locus for autosomal dominant 
polycystic liver disease, on chromosome 19p13.2 -13.1. Am J Hum Genet  2000;67:1598 -1604.  
36. Granth am JJ, Torres VE, Chapman AB, Guay -Woodford LM, Bae KT, King BF, Jr., Wetzel 
LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, 
Zhang X, Zhu F, Miller JP. Volume progression in polycystic kidney disease. N Engl J Med  
2006;354:2122 -2130.  
 Confidential  Page 44 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
37. Everson GT. Hepatic cysts in autosomal dominant polycystic kidney disease. Mayo Clin 
Proc 1990;65:1020 -1025.  
12 Appendices  
12.1 Appendix 1 Guidance for diarrhea management  
General recommendations:  
• Stop all lactose -containing products, alcohol  
• Stop laxatives, bulk fiber (Metamucil, Procter & Gamble), and stool softeners (docusate 
sodium; Colace, Roberts)  
• Drink 8 to 10 large glasses of clear liquids per day (water, Pedialyte (Ross),Gatorade (Quaker), broth)  
• Eat frequent small meals (bananas, rice, applesauce, Ensure, toast)  
• Stop high- osmolar food supplements such as Ensure Plus and Jevity Plus (with f iber) 
It is recommended that patients be provided loperamide tablets. It is mandatory that pa tients are 
instructed on the use of loperamide in order  to manage signs or symptoms of diarrhea at home. 
Patients should be instructed to start oral loperamide (initial administration of 4mg, then 2mg every 4 hours -maximum of 16 mg/day) at the first sign of loose stool or symptoms of abdominal 
pain. These ins tructions should be provided dur ing each office visit and the site should ensure 
that the patient understood the instruction. At the beginning of treatment, each patient should be specifically questioned regarding any ex perience of diarrhea or diarrhea rel ated symptoms. If 
symptoms were experienced, then the site should question the patient regarding the actions taken for these symptoms.  
Treatment of diarrhea grade 1 or 2  
Diarrhea grade 1 or 2 will be treated with standard loperamide (initial at first administration 4 mg, then 2 mg every 4 hours (maximum of 16 mg/day) or after each unformed stool).  
12-24 hours later:  
Diarrhea resolved 
• Continue instructions for dietary modification 
• Gradually add solid foods to diet  
• Discontinue loperamide after 12 -hours diarrhea -free interval  
Diarrhea unresolved 
Persisting diarrhea grade 1 or 2 will be treated with addition of opium tincture or dihydroc odeine 
tartrate tablets/injections with monitoring of patients condition to rule out dehydration, sepsis, i l-
eus) medical check and selected workup if pa tient does not need hospitalization (see section 
Diarrhea workup and additional test in the particular trial protocol). Observe patient for response to antidiarrheal trea tment.  
Persisting diarrhea grade 3 or 4 may be treated with hospitalization, high dose loperamide (ini-tial 4 mg, then 2 mg every 2 hours) and addition of opium tincture or dihydrocodeine tartrate tab-
 Confidential  Page 45 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
lets/injections, start of IV fluids and antibiotics as needed with monitoring of patients condition 
(to rule out dehydration, sepsis, ileus) medical check and workup (perform appropriate addition-
al testing). Observe patient for response.  
After 24 hours:  
Diarrhea resolved 
• Continue instructions for dietary modification 
• Gradually add solid foods to diet  
• Discontinue loperamide and/or other treatment after 12- hours diar rhea- free interval  
Diarrhea unresolved 
• If diarrhea still persisting (NCI CTC grades 1 and 2), after 2x 24 hours with high dose 
loperamide and opiates then admit to hospital and employ measures as for grade 3 
and 4 until diarrhea resolved  
• If diarrhea still persisting and progressed to NCI grades 3 and 4, employ measures described below.  
Treatment of diarrhea grade 3 or 4  
Severe diarrhea grade 3 or 4 may be treated with hospitalization, high dose lop eramide (initial  4 
mg, then 2 mg every 2 hours and addition of opium tincture or dihydrocodeine tartrate tab-lets/injections, start of IV fluids and antibiotics as needed with monitoring of patients condition 
(to rule out dehydration, sepsis, i leus) medical check and workup (see section Diarrhea workup 
and additional test in the particular trial protocol). Observe pa tient for response.  
After 24 hours:  
• If diarrhea persisting administer SQ Sandostatin/octreotide (100 -500 µg tid)  
• Continue IV fluids and antibiotics as needed  
• If diarrhea grade 3 or 4 still persists patients should receive opium tincture or dihy-
drocodeine tartrate injec tions SQ or IM  
• If diarrhea grade 3 or 4 is still persisting SQ Sandostatin/octreotide (500- 1000 µg tid) 
should be administered.  
• To control and/or resolve diarrhea, next cycle of treatment should be de layed by 1 or 
2 weeks. Treatment should be continued only when diar rhea resolved.  
Diarrhea workup  
Perform appropriate tests (Fine and Schiller 1999) . 
Spot stool analysis 
• Collect stool separating it from urine (special containers, analysis immediately, excep-
tionally freeze sa mples)  
• Blood 
 Confidential  Page 46 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
• Fecal leukocytes (Wright's staining and microscopy) or  
• Clostridium difficile toxin  
• Fecal cultures including Salmonella spp., Campylobacter spp., Giardia, Entamoeba, 
Crypto sporidium (which can lead to opportunistic infections in immunosuppressed pa-
tients), plus Shigella and pathogenic E. coli - enterotoxigenic, enterohemorrhagic etc., 
possibly Aeromonas, Pleisiomonas (if suspected exposure to contaminated w ater) 
Endoscopic examinations 
Endoscopic examinations may be considered only if absolutely necessary . The bowel is likely 
to be fragile with evidence of colitis and thus great care and caution must be exercised in under-
taking these invasive pr ocedures.  
• Gastroscopy to obtain jejunal fluid - re. bacterial overgrowth for cul tures and biopsy 
of proximal jejunum to assess extent of inflamm atory jejunitis  
• Sigmoidoscopy - reassessment of colitis  
12.2 Appendix 2 Guidance for hyperglycemia management  
Hyperglycemia is known to be associated with the treatment with SST  analogs .  Clinical studies 
of pasireotide in healthy volunteers and in patients with Cushing’s disease, acromegaly or car-cinoid syndrome have reported transient, asymptomatic increases in fasting and postprandial 
glucose levels.  Novartis has conducted 2 clinical studies ( [SOM230B2216]  and 
[SOM230B2124] ) to further understand the mechanism of pasireotide- induced hyperglycemia 
and to evaluate the clinical utility of anti -diabetes agents in the management of pasir eotide-
induced hyperglycemia.  Preliminary results suggest that pasireotide induces insulin suppres-sion, particularly in the postprandial period, as being the key mechanistic driver of hyperglyc e-
mia.  Based on the mechanisms of pasireotide- induced hyperglycemia and findin gs from the 
[SOM230B2124]  study, appropriate management for the pasireotide- induced hyperglycemia in-
cludes the use of oral anti -diabetic agents for mild to moderate hyperglycemia, such as incretin 
enhancers (e.g. GLP -1analogs  or DPP4 inhibitors or insulin secre tagogues).  Metformin is not 
recommended.  Insulin should be used for moderate to severe hyperglycemia. Clinical monito r-
ing and self -monitoring of blood gl ucose level  
Finger -stick measurements:  
Fasting assessment : Patients will have these checked during follow up assessments. 
The glucose values  from the will be  recorded and sent to Mayo Clinic. At screening all pa tients 
should be informed of the signs/symptoms of hyperglycemia and educated on how to complete the patient glucose diary. The glucose values do not need to be entered into the dat abase and 
should only be kept as source documentation.  
The below algorithm has been created as a general guidance tool on the management of pasi r-
eotide- induced hypergly cemia during this study. The choice of therapeutic agent is primarily at 
the discretion of the treating physician.  It is e ncouraged to follow the established guidelines from 
the ADA/EASD for the management of diabetes and consider a consultation with a diabetes ex-
pert as needed anytime during the study.   
 Confidential  Page 47 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Postprandial Plasma Glucose Criteria  
The patient should be instructed on the steps to take in the event a glucose value is elevated. 
The below criteria is recommended:  
 
 
* Value confirmed on 2 separate occasions during the observation period.  
Fasting  Plasma Glucose Criteria  
The patient should be instructed on the steps to take in the event a glucose value is elevated.  
 
 Confidential  Page 48 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
 
 
* Value confirmed on 2 separate occasions during the observation period.   
 
 Confidential  Page 49 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
Fasting plasma glucose or postprandial plasma glucose > 250 mg/dL (≥ CTCAE grade 3)  
 
 
12.3 Appendix 3 Guideline for the treatment of QT prolongation 
QT-related cardiology consultation/Holter monitoring  
If at any visit a QTcF > 500msec is observed, triplicate ECGs, each 2 -3 minutes apart, need to 
be taken approximately 1 hour after the initial ECG. The mean QTcF from the triplicate ECGs 
will be determined. If the mean QTcF is > 500msec, the patient has to interrupt ( SQ treatment)/ 
postpone (LAR treatment) study trea tment until a cardiologist has re -evaluated the ECG  (this 
will be done by the central cardiologist). The re -evaluation needs to be done as soon as pract i-
cal but within 7 days of the initial abnormal ECG. If the cardiologist confirms a mean QTcF > 
500msec, the patient has to  discontinue. Otherwise and if the cardiologist confirms that at least 
one ECG shows a QTcF > 480msec, the cardiac asses sments described for a confirmed QTcF 
> 480msec need to be followed.  
 Confidential  Page 50 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
If at any visit a 480msec < QTcF/mean QTcF ≤ 500msec is observed, the follo wing steps need 
to be tak en:  
A cardiology consultation must be sought as soon as practical but within 7 days of the in i-
tial abnormal ECG and the cardi ologist must re- evaluate the ECG (this can be done by 
the central cardiologist if the trial has one).  
If a QTcF > 480msec is NOT confirmed, no further action needs to be taken. 
If a QTcF > 480msec is confirmed, a cardiologist must perform a thorough ex amin ation (such as 
reviewing baseline ECG, concurrent medications and performing a cardiovascular examina tion, 
including at least a cardiac auscultation) to assess the patient for cardiovascular risk fa ctors.  
• If based upon the assessment by the cardiologist, the investigator consi ders that there is 
an acute cardiovascular safety risk and that the patient should not continue with study 
medication, the patient needs to be discon tinued immediately (discontinuation criteria to 
be fol lowed).  
• If following the examination by the cardiologist, the investigator considers that there is 
not an acute cardiovascular safety risk and that the patient could continue to receive 
study medication, a Holter ECG (24hr or 48hr d epending on the study) must be recorded 
soon as practical but within 7 days after the initial abnormal ECG / at the next pasir e-
otide/octreotide LAR injection (for studies using LAR). The Holter -ECG must be started 
30min prior to an injec tion of study medication.  
The results of the ECGs, cardiac examination, Holter -ECGs and the recommendation by the 
cardiologist must be evaluated by the investigator to determine whether the patient should con-tinue in the trial or not (discontinuation cr iteria to be followed).  
QT-related discontinuation criteria  
• Confirmed QTcF >480msec and discontinuation recommended by a cardiol ogist  
• Mean QTcF > 500 msec measured by triplicate ECGs  
• Significant arrhythmia findings from Holter monitoring such as:  
1. Any ventricular or supra- ventricular tachyarrhythmia associated with symptoms  of he-
modynamic co mpromise  
2. Sustained ventricular tachycardia (>30 sec) irrespective of symptoms  
3. Recurrent non -sustained VT (≥ 3 beats) during any 24- hour monitoring pe riod  
4. Torsades de Pointes (TdP)   
5. Cardiac arrest  
6. Pause >5 seconds  
7. Second or third degree AV block  
• New occurrence of clinically significant/symptomatic bradycardia  
• Increased risk of QT  prolongation by use of QT prolonging medication  
• Hypokalemia (<3.5 mmol/L) or hypomagnesaemia (<0.7 mmol/L) confirmed by repeat tes t-
ing that is either a new finding or accompanied by vomiting or diar rhea and not corrected by 
treatment  
 Confidential  Page 51 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
QT prolonging medicat ion 
The following drugs are generally recognized to have an association with QT pr olongation.  This 
list is not considered to be all inclusive and any questions regarding the QT prolongation poten-
tial should be discussed with the Novartis Medical Monitor.  
Drugs that are generally accepted by the QTdrugs.org Advisory Board of the Ar izona CERT to 
have a risk of causing to rsade de pointes are listed below.  
 
Generic Name  Brand Name  Class  
Bepridil  Vascor® Anti-anginal / heart pain  
Amiodarone  Cordarone®  Anti-arrhythmic / abnormal heart rhythm  
Amiodarone  Pacerone® Anti-arrhythmic / abnormal heart rhythm  
Disopyramide  Norpace® Anti-arrhythmic / abnormal heart rhythm  
Dofetilide  Tikosyn® Anti-arrhythmic / abnormal heart rhythm  
Ibutilide  Corvert® Anti-arrhyt hmic / abnormal heart rhythm  
Procainamide  Pronestyl® Anti-arrhythmic / abnormal heart rhythm  
Procainamide  Procan® Anti-arrhythmic / abnormal heart rhythm  
Quinidine  Cardioquin® Anti-arrhythmic / abnormal heart rhythm  
Quinidine  Quinaglute® Anti-arrhyth mic / abnormal heart rhythm  
Sotalol  Betapace® Anti-arrhythmic / abnormal heart rhythm  
Clarithromycin  Biaxin® Antibiotic / bacterial infection  
Sparfloxacin  Zagam® Antibiotic / bacterial infection  
Erythromycin  Erythrocin® Antibiotic;GI stimulant / bac terial infection; increase GI moti lity 
Erythromycin  E.E.S.® Antibiotic;GI stimulant / bacterial infection; increase GI moti lity 
Arsenic trioxide  Trisenox® Anti-cancer / Leukemia  
Astemizole  Hismanal®  Antihistamine / Allergic rhinitis  
Terfenadine  Seldane® Antihistamine / Allergic rhinitis  
Pentamidine  Pentam® Anti-infective / pneumocystis pne umonia  
Pentamidine  NebuPent® Anti-infective / pneumocystis pneu monia  
Probucol  Lorelco® Antilipemic / Hyperchole sterolemia  
Chloroquine  Aralen® Anti-malarial / malaria infection  
Halofantrine  Halfan® Anti-malarial / malaria infection  
Domperidone  Motilium® Anti-nausea / nausea  
Mesoridazine  Serentil® Anti-psychotic / schizophrenia 
Thioridazine  Mellaril®  Anti-psychotic / schizophrenia  
Haloperidol  Haldol® Anti-psychotic / schizophrenia, agit ation 
Pimozide  Orap®  Anti-psychotic / Tourette's tics  
Chlorpromazine  Thorazine® Anti-psychotic/ Anti -emetic / schizophr enia/ nausea  
Cisapride Propulsid® GI stimulant / heartburn 
Levomethadyl  Orlaam® Opiate agonist / pa in control, na rcotic dependence  
Methadone  Dolophine® Opiate agonist / pain control, na rcotic dependence  
Methadone  Methadose® Opiate agonist / pain control, na rcotic dependence  
Droperidol  Inapsine® Sedative;Anti -nausea / anesthesia a djunct, nausea  
 
 
 
 
  
 Confidential  Page 52 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
12.4 Appendix 4 SOM230 LFT Management Algorithm (s.c. and LAR St udies)  
 
 
Revised SOM230 Abnormal liver function discontinuation criteria:  
 
 
13 Procedures and instructions  
13.1.1  Publication of results  
Any formal presentation or publication of data from this trial may  be published a fter review and 
comment by Novartis and prior to any outside submission. Novar tis must receive copies of any 
intended communication in advance of publication (at least fifteen working days for present a-
tional materials and abstracts and thirty working days for manuscripts). These requirements 
acknowledge Novartis’ responsibility to provide peer input regarding the scientific content and 
conclusions of such publications or presentations. Principal Investigation/Institution shall have 
the final authority to determine the scope and content of its publications, provided such authority 
 Confidential  Page 53 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
shall be exercised with reasonable regard for the interests of Novartis and, in accord with the 
trial contract and shall not permit disclosure of Novartis confidential or proprietary i nformation.  
13.1.2  Disclosure and confidentiality  
The investigator agrees to keep all information provided by Novartis in strict conf idence and to 
request similar confidentiality from his/her staff and the IRB/IEC/REB. Study documents provi d-
ed by Novartis (investigators' brochures and other material) will be stored appropriately to en-sure their confidentiality. The information provided by Novartis to the investigator may not be 
disclosed to others without direct written authorization from Novartis, except to the extent nec-essary to obtain informed consent from pa tients  who wish to participate in the trial.  
13.1.3  Discontinuation of study  
Novartis reserves the right to discontinue any study under the conditions spec ified in the clinical 
trial agre ement.  
13.2 Ethics and Good Clinical Practice  
This study must be carried out in compliance with the protocol and the principles of Good Clini-
cal Practice, as described in Novartis standard operating pr ocedures and:  
ICH Harmonized Tripartite Guidelines for Good Clinical  Practice 1996. Directive 91/507/EEC, 
The Rules Governing Medicinal Products in the European Comm unity. 
US 21 Code of Federal Regulations dealing with clinical studies (including parts 50 and 56 con-
cerning i nformed consent and IRB regulations).  
Declaration of Helsinki and amendments, concerning medical research in humans (Recommen-
dations Guiding Physicians in Biomedical Research Involving Human Subjects). 
The investigator agrees to adhere to the instructions and procedures described in it and thereby 
to adhere to the principles of Good Clinical Practice that it con forms to.  
13.2.1  Institutional Review Board/Independent Ethics Committee  
Before implementing this study, the protocol, the proposed informed consent form and other i n-
formation to subjects, must be reviewed by a properly constituted I nstitutional Review Board / 
Independent Ethics Committee  / Research Ethics Board (IRB  / IEC / REB). A signed and dated 
statement that the protocol and informed consent have been approved by the IRB/IEC/REB 
must be given to N ovartis before study initiation. Any amendments to the protocol, other than 
administrative ones, must be reviewed by Novar tis approved by this committee.  
13.2.2  Informed consent  
We will explain to each subject (or legally authorized representative) the nature of the  study, its 
purpose, the procedures involved, the expected duration, the potential risks and benefits i n-
volved and any discomfort it may entail. Each subject must be informed that participation in the 
study is voluntary and that he/she may withdraw from the study at any time and that withdrawal of consent will not affect his/her subs equent medical treatment or relationship with the treating 
physician.  
This informed consent should be given by means of a standard written statement, written in 
non-technical language. The subject should read and consider the statement be fore signing and 
dating it, and should be given a copy of the signed document. If the subject cannot read or sign 
 Confidential  Page 54 
Oncology Clinical Trial Protocol (Version No. 0 5)  Protocol No. CSOM230CUS30T  
 
the documents, oral presentation may be made or signature given by the subject’s legally a p-
pointed representative, if witnessed by a person not i nvolved in the study, mentioning that the 
patient could not read or sign the documents. No patient can enter the study before his/her i n-
formed consent has been obtained. 
13.2.3  Declaration of Helsink i 
We will conduct the trial in accordance with the principles of the Declaration of Helsinki. Copies 
of the Declaration of Helsinki and amendments will be provided upon request or can be ac-
cessed via the website of the World Medical Associ ation at http://www.wma.net/e/policy/17-
c_e.html . 
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
 